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Zusammenfassung 
Die Multiple Sklerose (MS) ist eine entzündliche Erkrankung des zentralen 
Nervensystems, die mit Demyelinisierung sowie persistierendem Verlust von Axonen 
einhergeht. Remyelinisierung kann zu einem Teil den Verlust von Myelin kompensieren, 
während axonale Schäden irreversibel und potenziell dafür verantwortlich sind, dass 
Patienten progressive klinische Einschränkungen erfahren. Mit der fokalen axonalen 
Degeneration (FAD) wurde vor kurzem in einem Tiermodell der MS ein neuer, zellulärer 
Mechanismus der axonaler Schädigung beschrieben, welcher sequentiell Stadien durchläuft 
und schließlich zu irreversibler Fragmentierung des Axons führt. Erstaunlicherweise sind 
frühe Stadien dieses Prozesses noch reversibel. Um einen besseren Einblick in die 
molekularen Mechanismen zu bekommen, welche der fokalen axonalen Degeneration 
zugrunde liegen, habe ich in dieser Arbeit in einem Mausmodell der MS, der Experimentellen 
Autoimmunen Enzephalomyelitis (EAE), die intra-axonalen Kalziumkonzentrationen in 
entzündlichen Läsionen des Rückenmarks gemessen. Dafür setzte ich in vivo Multi-Photonen 
Mikroskopie ein, um Axone im intakten Rückenmark der lebenden Maus zu verfolgen. Zur 
Messung der Kalziumkonzentration verwendete ich transgene Mauslinien, die ein 
ratiometrisches, genetisch enkodiertes Kalzium-Sensorprotein unter dem neuronalen Thy1 
Promoter exprimieren. Zuerst analysierte ich die Expressionsmuster des Sensorproteins in 
spinalen Axonen, optimierte daraufhin den Bildgebungsansatz und etablierte die Messbasis in 
gesunden Kontrolltieren. Danach charakterisierte ich Morphologie und 
Kalziumkonzentrationen von Axonen in akuten und chronischen EAE-Herden. Während die 
Basiswerte in gesunden Tieren nur eine geringe Variabilität aufweisen, zeigen viele Axone in 
Tieren mit EAE deutlich erhöhte Konzentrationen von intrazellulärem Kalzium. 
Interessanterweise finden sich erhöhte Kalziumwerte nicht nur in den fortgeschrittenen 
Stadien von FAD, sondern auch in Axonen mit intakter Morphologie. Um zu bestimmen, 
inwiefern erhöhte Kalziumkonzentrationen für Axone die Wahrscheinlichkeit erhöhen, zu 
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degenerieren, verfolgte ich Kalziumkonzentration und Morphologie in einer Kohorte von 
über 300 Axonen über mehrere Stunden. Diese Experimente zeigen, dass Kalzium ein 
wichtiger prädiktiver Faktor für die anschließende, irreversible Degeneration ist. In 
Nachfolgestudien versuchen wir nun die Mechanismen zu bestimmen, die zur intra-axonalen 
Akkumulation von Kalzium führen. Dafür analysieren wir die Einflüsse von u.a. Glutamat 
Exzitotoxizität, Azidose, reaktiven Sauerstoff- und Stickstoffspezies (ROS/RNS) und der 
Funktionsumkehrung des Natrium/Kalzium Austauscher (NCX). Zusätzlich bewerten wir die 
Effekte von erhöhtem Kalzium, z.B. die Aktivierung von Ca2+-abhängigen Proteasen wie 
Calpain. Unser Ziel ist es, durch gezielte Manipulation dieser Mechanismen neue 
Therapiekonzepte zu entwickeln, welche in der Lage sind, die Progredienz der klinischen 
Einschränkung bei MS Patienten zu verhindern. 
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Summary 
Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system that 
features demyelination as well as persistent axonal loss. While demyelination can be partially 
compensated by remyelination, damage to axons is irreversible and thought to be responsible 
for the progressive disability seen in MS patients. How axons are damaged in MS remains 
unclear. Recently, our lab has identified a new cellular mechanisms of axon loss in an animal 
model of MS, that we termed “focal axonal degeneration” (FAD). FAD is characterized by a 
progression through sequential stages that ultimately leads to axon fragmentation. 
Surprisingly, axons in the early stages of FAD can still recover. To better understand the 
molecular mechanisms that determine the balance between degeneration or recovery, I have 
now investigated how intra-axonal levels of calcium, a prominent mediator of cellular 
degeneration and death, drive FAD. To obtain a readout of intra-axonal calcium levels in vivo, 
I used multi-photon microscopy to image axons in the lumbar spinal cord of transgenic mice 
expressing a ratiometric, genetically encoded calcium indicator protein under the neuronal 
Thy-1 promoter. First, I assessed the expression of the sensor protein in spinal axons, 
optimized the signal detection and characterized baseline calcium levels in healthy animals. 
Afterwards, I performed single time-point measurements of axons during the formation and 
remission of neuroinflammatory lesions in a commonly used animal model of MS 
(experimental autoimmune encephalomyelitis, EAE). My results show that whereas axonal 
calcium levels are tightly controlled in healthy animals, many axons in EAE mice show 
elevated levels of intracellular calcium. Interestingly, levels are not only increased in the more 
advanced stages of the degeneration process but also in a subset of axons that exhibit intact 
morphology. To address to what extent calcium levels predict the subsequent fate of axons, I 
followed changes in axonal morphology and calcium levels in a cohort of over 300 axons over 
several hours. These experiments indicate that calcium levels are a crucial predictor of axonal 
fate, with elevated levels indicating a high risk of subsequent degeneration. In follow-up 
studies we are now trying to identify the mechanisms that lead to intra-axonal calcium 
accumulation, and to evaluate, amongst other things, the effect of glutamate excitotoxicity, 
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acidosis, reactive oxygen and nitrogen species (ROS/RNS) and the reversed function of the 
Na+/Ca2+ exchanger (NCX). In addition, we analyse the downstream effects of elevated 
calcium, e.g. the activation of Ca2+-dependent proteases like calpain. The aim of these studies 
is to identify the key mechanisms that induce calcium influx in axons and represent new 
targets for strategies to limit progressive clinical disability in MS patients.  
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1. Introduction 
 
1.1 Multiple Sclerosis 
“We are constantly accepting, adapting and moving forward, together toward new 
normals” N. Lemelle, multiple sclerosis patient (Lemelle, 2011). 
It is hard to overestimate the impact that the diagnosis of multiple sclerosis has on an 
affected person’s daily life and attitudes. Since its description in the 19th century, this 
enigmatic disease has troubled many researchers because of its poorly understood cause, 
the variable mechanisms and the lack of long-term efficient medication. Of great 
importance is also the effect on society, where it remains the number one neurological 
disease of young adults and a major cause of early disability (Sospedra and Martin, 2005).  
Patients and their families, physicians and researchers share the strong wish to gain more 
insight into this complex phenomenon. The pace of discoveries that have dismantled some 
long-established dogmas about the disease has increased over the last two decades. The 
finding of shared mechanisms with other CNS diseases might even allow the transfer of 
some therapeutic principles. 
1.1.1 Definition 
Multiple Sclerosis is a chronic inflammatory disease of the human central nervous system. 
It features disseminated demyelinated plaques and focal lymphocytic infiltration in brain and 
spinal cord as well as progressive neuro-axonal degeneration (Compston and Coles, 2008; 
Compston et al., 2005; Friese et al., 2014). Since in principle the entire CNS can be affected, 
possible clinical signs include a large variety of neurological deficits, which comprise for the 
most part motor, sensory, visual and autonomic systems. However, many other symptoms can 
occur, e.g. cognitive impairment, fatigue, vertigo and tremor (Compston and Coles, 2008).   
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1.1.2 Diagnosis and clinical course 
The entity of the clinically isolated syndrome (CIS) describes the affection of one site at 
one timepoint (e.g. optic neuritis). It forms the presenting symptom for 80% of the patients 
(Compston and Coles, 2008) and will remain the diagnosis until the so-called temporal and 
spatial dissemination have settled the final diagnosis of MS. This concept requires multiple 
lesions that affect different areas (and therefore neurological systems) at multiple timepoints. 
It has been implemented in the by now twice-revised McDonald criteria for MS diagnosis 
(McDonald et al., 2001; Polman et al., 2005; 2011). Even though clinical evidence still plays the 
greatest role in the establishment of the diagnosis, paraclinical findings have become 
increasingly important: These include MR Imaging, biomarkers in the cerebrospinal fluid and 
retinal optical coherence tomography (OCT). For instance, a lesion-positive brain MRI at 
presentation with a CIS is highly predictive of a long-term MS diagnosis, with over 80% 
suffering MS after 10 years (O’Riordan et al., 1998). The use of gadolinium enhancement 
allows distinguishing of inactive and active lesions, which renders an early diagnosis possible 
and therefore speeds up treatment planning.  
The course of the disease in an individual patient is often unpredictable and can unfold in 
strikingly manifold ways. In principle, one must distinguish between two clinical entities:  
either a disease modality where symptoms flare up (relapse) and then eventually disappear 
without any remnants (remission), or a constant worsening of symptoms referred to as 
progressive MS. Patients can have one of these manifestations from the onset of disease, which 
allocates them to the groups of relapsing-remitting (RR)-MS or primary-progressive (PP)-MS, 
respectively. However, it is the combination of these two different types – meaning a RR-MS 
that is secondarily followed by a progressive phase (SP) – that represents, with around 70% of 
patients, the most frequent type of disease (Weinshenker et al., 1989). 
Remarkably, no matter if the progressive phase occurs secondarily to RR-MS or if it 
started a priori, it leads around a similar median age to the appearance of irreversible 
disability (e.g. limited walking without aid at a median age of around 44 years). Many of the 
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individuals that do show an earlier onset of irreversible disability were also diagnosed at a 
younger age. This renders the age of diagnosis a much stronger factor in predicting the start of 
irreversible disability than the entity (RR-MS vs. PP-MS) or inflammatory activity of the 
disease (Confavreux and Vukusic, 2006). In addition, there is also a form of benign MS in 
about 10% of patients that will do well for more than 20 years (Noseworthy et al., 2000). 
Taken together, this variability in the disease course suggests not only one, but several 
underlying pathomechanisms that might act partially independently of each other. 
Even though in most cases physical impairment becomes severe with increasing age, over 
all life expectancy is shortened only slightly in multiple sclerosis. One should note however 
that there are rare cases reported, where a fulminant disease leads to patients deceasing just a 
few months after the diagnosis. Further, suicide rates among MS patients show a more than 
sevenfold increase compared to age-matched control groups (Sadovnick et al., 1991) 
 
Figure 1  Disease course of multiple sclerosis 
(A) Schematic representing the different clinical courses of multiple sclerosis. The green graph depicts 
waxing and waning of clinical symptoms that manifest in patients in the relapsing-remitting form (RR-MS, 
left) and the slow progression to progressive disease (SP-MS, right), where symptoms persist. Primary 
progressive (PP-MS) form skips a preceding phase of relapse and remission and resembles SP-MS.  (B) 
Assumed underlying pathological processes: The violet bars propose frequent flaring of inflammatory 
activity that mostly does not reach clinical relevance. Neuroaxonal loss and resulting brain atrophy occur 
simultaneously, and seem to be a better correlate of progressive symptoms. Adapted from Compston and 
Coles, 2008. 
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1.1.3 Pathology and pathogenesis 
The characteristic pathological feature of multiple sclerosis is the demyelinated plaque, an 
initially hypercellular and later hypocellular area, characterized by the loss of myelin and the 
formation of astrocytic scars. Besides the common assumption that the responsible 
mechanism is a primary inflammatory process caused by an autoimmune reaction against a 
myelin component, current pathogenesis models suggest a dualism of two interconnected 
arms: inflammation and neurodegeneration. Which of these comes first, or if one causes the 
other, is not known.   
1.1.3.1 Immunopathogenesis 
One main component that initiates the inflammatory part of the disease process is the 
migration of autoreactive lymphocytes across the blood-brain barrier. This is probably due to 
the failure of regulatory T-cells to suppress these effector cells (Viglietta et al., 2004) and/or 
the overexpression of survival factors (e.g. β-arrestin1) that makes the apoptosis of 
autoreactive cells go awry (Shi et al., 2007). The target antigen has so far been proven not to be 
one single CNS protein, like the myelin-specific proteins used in MS animal models or 
Aquaporin-4 in the sister-disease neuromyelitis optica (Lennon et al., 2005). It is proposed to 
be either a rather nonspecific, polyclonal activation of T and B cells by bacterial or viral 
antigens, or a result of structural homology between a self-protein and a pathogen-protein, a 
phenomenon commonly known as molecular mimicry (Sospedra and Martin, 2006; Steinman 
et al., 2002). 
 Inflammatory, demyelinating plaques cluster around the lateral ventricles and corpus 
callosum, in the cortex and subcortical white matter, the optic nerves, in the brainstem and 
throughout the spinal cord (Compston and Coles, 2008). In addition to T-lymphocytes, 
mainly macrophages but also B-cells, plasma cells and NK-cells can be found in the affected 
CNS. Whereas B-cells have been detected in the brain parenchyma, it is assumed that 
differentiation, maturation and the secretion of antibodies happens in the meningeal spaces 
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and the Virchow-Robin spaces, leading to a compartmentalised humoral immune response 
with intrathecal antibody production that is assumed to contribute to cortical pathology in the 
later stages of the disease (Magliozzi et al., 2007). Diagnostically relevant evidence comes from 
the appearance of so-called ‘oligoclonal bands’ on protein electrophoresis gels of lumbar 
puncture fluid obtained from MS patients. They are the correlate of the autoantibodies 
present in the subarachnoid compartment. 
1.1.3.2 Demyelination 
A major hallmark of MS is the formation of multiple demyelinating lesions throughout 
the CNS. Historically, researchers have assumed that the demyelination is a primary process 
where the immune system has been tricked into seeing CNS myelin as foreign and therefore 
attacks and removes it. By now, four different types of demyelinating lesions have been 
described. They could potentially appear in different subpopulations of MS patients and for 
each has been suggested a distinct underlying mechanism (Lassmann et al., 2001). 
Demyelination may be induced by macrophages, which have been activated by Th1 cells and 
secrete toxic factors (including TNF-α and ROS/RNS), resulting in pattern I. In pattern II, 
specific demyelinating antibodies and complement is described as the main factor - similar to 
animal models that include immunization with myelin-specific proteins. The so-called “distal 
oligodendrogliopathy” of pattern III supposedly leads to degenerative changes in the distal 
processes of the oligodendrocytes that surround axons and is followed by apoptosis. In this 
case, a demyelination occurs that appears similar to white matter viral infections or ischemia. 
The presumed mechanism for pattern IV is a primary oligodendrocyte degeneration but it 
seems to be less frequent than the other patterns. 
1.1.3.3 Neuroaxonal damage 
Axonal injury and loss has been described since the very first publications about MS and is 
considered to be a major feature in inflammatory lesions. However, for a long time it had been 
thought to be a secondary process to the inflammatory, demyelinating attacks and therefore 
therapies have focused mainly on reducing inflammatory activity and lesion load. A change of 
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paradigm is now taking place, attributing the irreversible neuroaxonal loss a major role in the 
pathogenesis of the disease and depicting it as the main correlate for cumulative neurological 
disability (Bjartmar et al., 2000).  
MRI studies have detected hypointense T1 ‘black holes’, cortical lesions and atrophy of the 
brain and spinal cord early in the disease course (Barkhof et al., 2009; Chard et al., 2002). 
Magnetic resonance spectroscopy (MRS) studies showed a reduction of N-acetyl-aspartate 
(NAA, a marker of axonal integrity) in the white matter of MS patients that correlates with the 
extent of their neurological deficits (Stefano et al., 1998; 2005). 
 
Figure 2  Persistence of a “black hole” in the brain MRI of a multiple sclerosis patient 
T1-weighted spin-echo MRI of a multiple sclerosis patient, first image constrast-enhanced. Two 
gadolinium-enhancing lesions (green boxes) that appear hypointense without contrast (not shown) 
subsequently become isointense on follow-up, consistent with remyelination. An old lesion, presenting as a 
hypointense “black hole” (blue box) remains the same, correlating with a chronic lesion showing axonal loss. 
Adapted from (Barkhof et al., 2009) 
 
Axon loss has also been detected in the retina. The easy optical access to unmyelinated 
CNS axons in the retinal nerve fibre layer (RNFL) allows for unprecedented measurement of 
axons at micrometre resolution in vivo, using the technology of optical coherence tomography 
(OCT). With this tool, RNFL neurodegeneration in patients with MS who had no prior 
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clinical history of optic neuritis was found to be increased tenfold compared to disease-free 
controls (Petzold et al., 2010). 
In histopathology, immunohistochemistry has been used to detect axonal pathology. 
Amyloid precursor protein (APP) is a protein that is transported along the axon and, when 
the cytoskeleton breaks down, accumulates to a degree that it becomes detectable. Stainings 
for APP have shown early axon loss in lesions and at the border of active lesions (Ferguson et 
al., 1997; Kuhlmann et al., 2002). Another staining, called SMI-32, shows non-phosphorylated 
neurofilament that is also known to accumulate in the process of axon injury.  Studies using 
SMI-32 immunohistochemistry also revealed axon loss in active lesions and at the border of 
chronic lesions (Trapp et al., 1998).  
A positive correlation of axonal injury and inflammation (characterized by the infiltration 
density of macrophages and T-cells) has been shown in multiple sclerosis lesions (Bitsch et al., 
2000). This suggests that immune-initiated mechanisms directly lead to axon damage. 
However, Kornek et al. correlated axon damage with lesional stages, assigned by the presence 
and antigenic composition of myelin debris in macrophages, and found that acute axon loss 
was found even in inactive lesions. This renders the pathogenesis even more intriguing: it 
suggests processes, that will damage axons not only in a setting with nearby immune cells, but 
also an ongoing process in the “burnt-out” lesions that slowly contributes to the total axonal 
loss and therefore increasing disability (Kornek et al., 2000; Lassmann, 2003). If the 
mechanisms that underlie these different settings of axonal damage are related or distinct 
remains elusive. 
1.1.4 Animal Models 
 “One of the most enduring models of human disease” (Steinman, 2003), Experimental 
Autoimmune Encephalomyelitis (or Experimental Allergic Encephalomyelitis, EAE), has been 
used for more than 80 years to study autoimmune-mediated damage to CNS structures. EAE 
is an inflammatory, demyelinating disease of the CNS that has many clinical and pathological 
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similarities with MS. It was originally inspired by the “paralytic accidents” that arose from 
vaccination with rabies-infected rabbit spinal cord by Louis Pasteur in 1885. Rivers and 
colleagues immunized rhesus monkeys with rabbit brain emulsion to trigger a demyelinating, 
sterile encephalomyelitis (Rivers and Schwentker, 1935; Rivers et al., 1933). The intention of 
the original experiment was to understand acute disseminated encephalomyelitis after viral 
infections, not MS. Complete Freund’s adjuvants, a solution containing inactivated 
mycobacteria tuberculosis and mineral oil that triggers a strong immune response, were 
implemented to produce a highly reproducible model of paralysis and white matter 
inflammation (Kabat et al., 1947). Since then, a lot of effort has been put into refining this 
model disease to resemble the MS disease course, its immunopathology, and to make it a 
suitable paradigm for preclinical therapy studies. In simple terms, two main methods of EAE 
induction have been used: an actively-induced EAE (aEAE) versus a passively-transferred 
variant (pEAE). The basic protocol for aEAE is the immunization with self or foreign proteins 
that find themselves in the white matter of the CNS, such as myelin basic protein (MBP), 
myelin oligodendroglial glycoprotein (MOG) or proteolipid protein (PLP) (Steinman, 1999). 
There are many experimental permutations concerning the mouse strains used, as well as the 
peptides or proteins taken as antigens (that by now include several more myelin, neuronal and 
glial antigens). Actively-induced EAE mostly follow a similar disease course that evolves 
acutely and eventually wanes to different degrees of residual disease. To include clinical events 
such as relapsing and remitting episodes of paralysis, more suitable EAE models have been 
developed (Brown and McFarlin, 1981; Lublin et al., 1981). Problematic aspects of aEAE 
include the obligatory active induction. Also, there are rather inelegant side effects like the 
large deposits of adjuvants that may interfere with the global immune reactivity of the 
immunized animal. 
 In another approach, EAE is passively transferred (pEAE) by in vitro activated 
autoimmune T-cell lines. This “adoptive transfer model” has been useful in drug screening, 
functional gene characterization (Krishnamoorthy and Wekerle, 2009) and to elucidate the 
specific roles and capability of T-cell subtypes to induce a CNS inflammation. However, bulk 
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infusions of immune cells, which have been activated to their maximum in vitro, do not 
necessarily resemble the situation in MS. Current EAE development focuses also on the 
creation of spontaneous models, achieved by transgenic mice that carried T-cells and B-cells 
with myelin-specific receptors (Krishnamoorthy et al., 2007).   
To improve the relevance of EAE studies to MS, efforts have further been undertaken to 
humanize the critical parts of disease initiation: mice that are transgenic for human MHC-
class II and a T-cell receptor from a MS patient’s myelin-specific TH clone (Gregersen et al., 
2004) are beginning to reproduce some of the various clinical manifestations and 
corresponding CNS lesions of multiple sclerosis. It is therefore postulated that these 
spontaneous models will develop into a more valid model for translational research than the 
traditional ones (Friese et al., 2006). 
 
1.2 Axon degeneration 
When considering the molecular mechanisms of axonal damage, two different phases of 
axonal disintegration have to be distinguished: the trigger of axonal damage and the 
downstream pathways of axonal dissolution. Although the triggers of axonal injury seem to be 
specific for inflammatory conditions, such as MS, the downstream mechanisms of axonal 
dissolution appear similar in a variety of different pathological conditions of the nervous system, 
including inflammation, ischemia, or trauma (Lassmann, 2003).  
1.2.1 Axon degeneration programs 
Many neurological disorders have been found to include axon degeneration. A range of 
insults can trigger a dismantling of axons, including not only CNS injury, genetic defects and 
toxins, but also a milieu that is a result of metabolic disturbance, myelin disorders, ischemia or 
inflammation. Downstream axonal dissolution shows a certain diversity, but retains, however, 
many common features. Several different degeneration phenotypes have been described that 
will be discussed below. 
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One such type of axonal degeneration that has been heavily focussed on is Wallerian 
degeneration (WD). This is an axon degeneration program that occurs after axonal 
transection, where the axon region distal to the site of injury starts degenerating about 1.5 
days after the lesion. The axonal skeleton first disintegrates to form axonal swellings, forming 
a “beads-on-a-string” like appearance, with the axonal membrane subsequently breaking 
apart. This is followed by degradation of the myelin sheath and infiltration by phagocytic cells. 
Even though August Waller described his observations over 150 years ago, in recent decades 
the topic has been resurrected by attempts to decipher the mechanism behind the effect of 
WldS, a mutant gene whose overexpression leads to the phenotype of a tenfold-delayed axon 
dismantling compared to wildtype Wallerian degeneration (Lunn et al., 1989; Perry et al., 
1990). To this day, several other mutations have been found to delay the same process for 10 
days or more (Babetto et al., 2013; Mack et al., 2001; Osterloh et al., 2012) and great effort has 
been put into delineating the specific roles these factors have in a putative post-injury 
signalling pathway. One prominent enzyme family that slows Wallerian degeneration when 
overexpressed within axons are the nicotinamide mononucleotide adenylyltransferases 
(NMNATs), also comprising WLDS which contains NMNAT1.  
The importance of this is twofold: firstly, these findings show that axonal degeneration is 
more than plain atrophy of axons that lack nutrition supply when transected, but is rather an 
active signalling process that can be elicited by various conditions and that involves many 
different molecular factors. Secondly, components of the pathways can be a shared hallmark 
of a variety of conditions where axons are disassembling. Attempts to classify observed 
degeneration processes have been focussed to a large extent on changes in morphology. Axon 
degeneration seen in peripheral neuropathies, ALS and other disorders have been assigned the 
term “Wallerian-like degeneration” due to the presence of ovoids of degenerating myelin, 
fragmentation of distal axons and, in the CNS, large axonal swellings. Many different diseases 
and animal models have in the meantime been assessed regarding their susceptibility to the 
effect of WLDS  and overexpressed NMNAT isoforms. One can therefore also distinguish 
between conditions where these factors play an important role: “WLDS-sensitive 
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degeneration” (e.g. models of traumatic nerve injury, glaucoma, toxic neuropathy or 
Parkinson’s disease) and conditions where there has been no or only little effect, e.g. ALS, 
spinal muscular atrophy or hereditary spastic paraplegia (Conforti et al., 2014). In EAE, a 
moderate effect of WLDS is presumed (Kaneko et al., 2006). 
With the technological advancement in bioimaging approaches, other processes of axonal 
degeneration have also been identified that are different in both temporal progression and 
morphological changes compared to WD. Acute axonal degeneration (AAD) describes a 
sudden dieback of proximal and distal ends of a transected axon in the first few hours after 
lesion, that lasts less than five minutes and that is strongly affected by the WLDS mutation 
(Kerschensteiner et al., 2005). Even though many morphological characteristics of AAD seem 
comparable to WD, it presents itself as an independent entity that temporally precedes 
characteristic WD in a spinal cord injury model.  
Recently, another entity of axonal degeneration was characterized under the 
neuroinflammatory conditions seen in EAE. Focal axonal degeneration (FAD) describes the 
spontaneous formation of semi-stable focal axonal swellings inside inflammatory foci that can 
persist for days. Interestingly, they can progress to either fragmentation or morphological 
recovery. The axon fragmentation spreads slowly from the sites of disruption (3.5 µm min−1) 
in both directions and stops with the formation of terminal bulbs on both stumps. It often 
appears to start at the nodes of Ranvier and can occur almost synchronously at several sites at 
the same time. FAD can be detected both in demyelinated as well as myelinated axons, hence 
weakening the general belief that damage to myelin is a prerequisite for axon damage. It also 
tends to affect small calibre more than large calibre axons. The same morphological features 
of degeneration could be detected in actively demyelinating multiple sclerosis lesions and 
many axons that appeared swollen or fragmented were shown to be still wrapped in myelin 
(Nikić et al., 2011). 
Introduction 
 
12 
 
Figure 3  Focal axonal degeneration 
(A) Confocal projection image showing fluorescently labelled axon (white), activated 
macrophages/microglia (magenta) and T-cells (cyan) in an acute spinal cord lesion in EAE. (B) Selected 
axons taken from (A) showing different stages of focal axonal degeneration: intact morphology (stage 0, 
green), focal swellings (stage 1, yellow) and fragmentation (stage 2, red). (C) Fate of axons originally 
presenting with stage 1 morphology over the timecourse of 4 days, stages of degeneration color-coded as in 
B. (D) In vivo 2-photon time-lapse images of an axon showing recovery from stage 1 to stage 0. Scale bars: 10 
µm. Adapted from (Nikić et al., 2011) 
1.2.2 Molecular mechanisms of axon degeneration 
There are multiple elements in the puzzle of a putative degeneration sequence that all have 
been proven to be important factors, but their order and grade of importance has yet to be 
sorted out. Reactive oxygen species (ROS), reactive nitrogen species (RNS) and mitochondrial 
failure have been proposed to play a crucial role in axon damage, especially under 
inflammatory conditions (Dutta et al., 2006; Kapoor et al., 2003; Smith et al., 2001). In the 
setting of FAD, subcellular changes can be observed in axons within lesion sites: in swellings 
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as well as in normal appearing axons, mitochondria present a swollen and shortened 
dysmorphic shape accompanied by a decrease in membrane potential. These alterations could 
be reproduced by applying ROS or RNS to the healthy spinal cord. Mononuclear phagocytes 
have been suggested to be a major source of ROS/RNS. They can be found spatially close to 
degenerating axons for prolonged periods of time (Nikić et al., 2011). This is in line with the 
assumption that oxidative damage to mitochondria plays an important role in MS (Haider et 
al., 2014; Lin and Beal, 2006). The subsequent effects of mitochondrial malfunction can be 
manifold: lowered ATP levels, generation of ROS, impaired calcium buffering leading to an 
imbalance of cellular homeostasis, activation of the mitochondrial permeability transition 
pore (mPTP), as well as the release of pro­apoptotic signals and other cell death mechanisms 
(Court and Coleman, 2012). However, the exact sequence of these events and a potential 
interplay among them remain unknown. 
Mitochondrial damage is closely related to another player in the process of degeneration: 
Increased intracellular calcium concentrations have been shown to play a fundamental role in 
different models of axon degeneration. For example, in Wallerian degeneration, an influx of 
extracellular calcium was proposed to be necessary and sufficient for induction, probably 
triggering activation of calpains that degrade the cytoskeleton (Schlaepfer, 1974). In a parallel 
study to this work, an in vivo study of spinal cord contusion, we have found a calcium rise in a 
large population of axons that drives axon loss in a calpain-dependent fashion (Williams et al., 
2014). Under the inflammatory conditions of MS, EAE and Acute Optic Neuritis (AON), an 
altered expression of Ca2+ channels and the Na+/Ca2+ antiporter has been shown and suggested 
to play a role in mediating calcium overload of the cells (Craner et al., 2004a; 2004b; Friese et 
al., 2007; Gadjanski et al., 2009; Rossi et al., 2010). The question of whether axonal calcium is a 
crucial factor for axon degeneration in EAE, and what the main effectors and sources of intra-
axonal calcium changes are, remains elusive. Finding the answer to these questions motivated 
the development of the approach described in this work here. 
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1.3 In vivo visualization of neuronal calcium levels 
Imaging cellular, subcellular and even molecular processes over time in the intact tissue of 
rodents has recently become possible with the great advances in light microscopy techniques. 
The ability of fluorescence microscopy to probe non-translucent tissues and advances in 
transgenic technology that allow to specifically label different cell types and structures makes a 
wide variety of imaging paradigms possible. However, a comprehensive understanding of the 
tools used is essential to interpret the data that is being generated by these novel techniques. 
1.3.1 Intravital 2-photon microscopy of the nervous system 
The desire of scientists to study structure, function and dysfunction in the complex 
structure of the CNS has always been great. However, to achieve this, easy access to the organ 
to be imaged had to be established, often resulting in ex-vivo explant models or slice cultures. 
If an organ like the spinal cord is exposed by sophisticated surgery techniques (Misgeld et al., 
2007), the rays of a conventional light microscope would only be able to resolve signals on the 
very surface. This is due to strong scattering of the light, resulting in an image that appears 
blurred and with suboptimal resolution. Even though the poor z-resolution of an 
epifluorescent excitation can be overcome by introducing a pinhole to achieve confocality (to 
exclude light that comes from above and below the focus), tissue penetration of visible, 
confocal laser lines is too poor to allow for well-resolved imaging in greater depth. To move 
fluorescent microscopy into the field of non-linearity was an ingenious step by the pioneers of 
the early 1990s that developed the two-photon microscope (Denk and Svoboda, 1997; Denk et 
al., 1990; 1995; Helmchen and Denk, 2005; Zipfel et al., 2003).  
Two-photon laser-scanning microscopy combined with in-vivo fluorescent labelling 
techniques is the dominant method that has evolved out of the non-linear microscopy field. It 
made non-invasive imaging of intact tissue possible with an improved resolution in XY and Z, 
managing imaging depths up to almost 1 mm with an unprecedented signal-to-noise ratio 
compared to other fluorescence microscopy methods. The principle behind the method is that 
of a “higher-order” interaction between a defined wavelength of excitation light and the 
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corresponding fluorophore.  In conventional fluorescent microscopy, a single photon excites a 
fluorophore to move its electrons to a higher energy state, rendering it a linear process that is 
directly proportional to the light intensity. In nonlinear microscopy, multiple photons of 
higher wavelength and therefore lower energy can be used to generate contrast in matter. 
However, they need to be highly concentrated in space and time to allow for sufficient 
excitation of the fluorophores. High spatial densities can be generated by using a high 
numerical aperture (NA) objective to focus the laser beam. Concentration in time requires the 
use of sophisticated lasers that emit ultrashort pulses, which last only femtoseconds but show 
correspondingly high peak intensities (Helmchen and Denk, 2005). 
 
Figure 4 Basic principles of 1 and 2-photon excitation 
  (A) Jablonski diagram depicting one-photon and two-photon absorption. The emission of a photon of 
a “green” wavelength (e.g. 520 nm) can be evoked by the excitation with “blue” (e.g. 488 nm) or a high 
density of near-infrared photons (e.g. 960 nm). (B) In linear, single-photon microscopy, an entire cone of 
fluorescence light is generated (left), whereas in multi-photon, nonlinear excitation, the signal is localized in 
the point spread function of the focal spot (right) (B Modified from Zipfel et al., 2003). 
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The advantages of the technique are twofold: First, in contrast to linear fluorescent 
microscopy, the photons used for excitation are of a longer wavelength (near-infrared) than 
the emitted photons of the sample. This facilitates tissue penetration of the excitation light-
beam strongly, since biological samples scatter shorter wavelengths more and present a variety 
of endogenous absorbers that will render the light energy to heat and result in tissue damage. 
Second, the high spatial and temporal photon density needed will in theory only be reached in 
the actual focus of the laser beam – neither below nor above. This results in an automatic 
selection for the perifocal z-volume without the application of a pinhole that decreases signal 
intensity. As there is little to no excitation of out-of-focus volumes this leads to less 
photobleaching and toxicity in the biological sample. The signal can be detected by “external” 
detectors, also referred to as non-descanned detectors (NDDs), which bypass the excitation 
lightpath including the scanning mirrors. Thereby they detect all the photons falling into the 
large opening angle of the high-NA objective. This again leads to a stronger in-focus signal 
without harming the rest of the specimen.  
When it comes to in vivo observations in the CNS, the development of new molecular 
biological tools to label the structures of interest have proved equally important as the 
invention of new imaging modalities. The generation of transgenic mice that show a strong 
labelling of neurons and their processes with fluorescent proteins was of particular 
importance (Misgeld and Kerschensteiner, 2006). To be able to follow a single neuronal cell or 
its neurites in space and time, a Golgi-like staining pattern is needed in living animals. This 
was achieved by expressing different spectral variants of fluorescent proteins (XFPs) under the 
control of a modified Thy1-promoter element (Feng et al., 2000). In addition to transgenic 
mouse lines that display sparse patterns of neuronal labelling, other lines are available that 
have dense or almost full labelling, which enables the researcher to analyse large populations 
of neurons in a single experiment. Glial cells such as astrocytes, oligodendrocytes, microglia 
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and immune cells can also be specifically studied in vivo using a similar approach (Pfrieger 
and Slezak, 2012). 
The tools available for fluorescent in vivo microscopy even allow imaging on the level of 
subcellular structures and can give a functional readout of various intracellular molecules and 
ions in the CNS.  The possibilities include, for example, the assessment of mitochondrial 
transport (Misgeld et al., 2007a), microtubule dynamics (Kleele et al., 2014), indicators of 
intracellular metabolic state like ATP or NADH (Berg et al., 2009; Zhao and Yang, 2014), pH 
and redox state (Breckwoldt et al., 2014; Gutscher et al., 2008; Tantama et al., 2011).  
One cellular measurement that has traditionally been of outstanding interest to 
neurophysiologists is intracellular calcium, as it not only is a key player in cellular signalling 
and pathology, but is also a reliable readout of activity, rising concomitantly with increasing 
numbers of action potentials during cellular firing. Calcium can be monitored in vivo using 
synthetic or genetically encoded calcium sensors, and therefore provide insight into 
physiological activation states or pathological mechanisms of cells and, particularly for this 
study, neurons. 
1.3.2 Genetically encoded calcium indicators 
Calcium is a crucial and versatile intracellular player responsible for a multitude of 
functions in a variety of cell types in biological organisms. Processes that include Ca2+ operate 
over a wide time range (from neurotransmitter release happening at the microsecond scale to 
gene transcription, which lasts for minutes and hours) and involve concentrations that span 
several orders of magnitude. Whereas nanomolar quantities trigger synaptic vesicle release, 
the influx of micromolar concentrations of Ca2+ is seen in cell death. The appropriate kinetics, 
binding capacity and signal response of  Ca2+ sensors are therefore of paramount importance if 
one wishes to assess Ca2+ signals in vivo (Grienberger and Konnerth, 2012). Many different 
indicators have been produced or bioengineered in the last decades to match this variety of 
applications in research. 
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To be able to study Ca2+ signals in the rodent CNS under pathological conditions, a 
suitable sensor would need to generate a decent signal for robust Ca2+ transients, a stable 
baseline and should interfere neither with intracellular ion homeostasis nor with the cell’s 
endogenous Ca2+ signalling. A non- or minimally invasive way to deliver the indicator to the 
tissue volume of interest would allow the distinction between experiment-induced damage 
and the actual disease paradigm. A major advance towards this ideal was the generation of 
genetically encoded calcium indicator proteins (GECI). These sensors are based on a stretch 
of DNA and allow engineering by any technique that the recombinant DNA toolbox offers. 
The sequence coding for the sensor can be delivered by direct insertion into the genome by 
fertilized egg manipulation leading to transgenic mouse production, or with the appropriate 
viral vector into cells of postnatal animals. The sensor protein is then formed within the cell in 
situ (Mank and Griesbeck, 2008).  Stable cellular expression can be achieved in all kinds of 
organisms including rodents. 
The GECIs are fluorescent protein complexes with calcium binding properties that change 
their emission and/or excitation behaviour according to the concentration of Ca2+ around 
them. Two distinct pathways of sensor development have been followed (Griesbeck, 2004; 
Miyawaki et al., 1997): In one, a single fluorophore is used as the basis to form an indicator 
that changes the signal intensity upon binding. These sensors have become very popular 
because of the high dynamic range they exhibit. They have turned out to be ideal to monitor, 
for example, the activity of single neurons and networks in response to external stimuli. 
However, as only changes in Ca2+ can be detected without a reference baseline, it appears 
difficult to use these single fluorophore indicators in disease models. In the second approach, 
a dual wavelength sensor works by means of fluorescence resonance energy transfer (FRET) 
between two different fluorescent proteins, providing a ratiometric measurement that can be 
used to directly quantify intracellular Ca2+ levels (Garaschuk et al., 2007).  
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Fluorescence (also referred to as Försters) Resonance Energy Transfer is a physical 
phenomenon that occurs when two neighbouring fluorescent molecules change their distance, 
orientation or conformation. At a distance of 100 Å and below, the so-called “donor” 
molecule will transfer energy non-radiatively to the “acceptor” molecule, leading to the 
emission of a photon by the acceptor. A prerequisite for this to occur is that the emission 
spectrum of the shorter-wavelength donor has to overlap with the excitation spectrum of the 
acceptor, which exhibits a longer wavelength (spectral overlap). The relative orientation of the 
donor absorption and acceptor transitions moments and the refractive index are also factors 
that influence the transfer rate of the process (Jares-Erijman and Jovin, 2003). 
This phenomenon enables the creation of a “nanoscale ruler”, which in turn allows the 
visualization of conformational changes of single molecules, simply by attaching fluorescent 
reporters to its different domains. Indeed, when the Ca2+ binding domains of proteins are 
bound by Ca2+, conformational changes in the structure occur. Different teams of researchers 
have therefore taken proteins (or some of their domains) known to bind calcium, attached 
enhanced spectral variants of green fluorescent protein (GFP) and created a protein that is 
able to report calcium levels. The read-out is the ratio of the two fluorophores’ signal that 
changes when FRET occurs. In one approach, calmodulin and its binding peptide M13 from 
myosin light chain kinase were inserted between BFP and GFP (Miyawaki et al., 1997). This 
sensor and its enhanced versions are referred to collectively as the family of “Cameleons”. As 
there is a variety of endogenous functions, interactions of the Cameleons with some of the 
many calmodulin-binding proteins in the cell are difficult to rule out. Thus, a better solution 
was the complete replacement of the highly regulated calmodulin with another Ca2+-binding 
protein that is less likely to interfere in the signal transduction networks of rodent neurons.  
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Figure 5  Structure of a FRET based genetically encoded calcium indicator  
(A) The basal structure of the sensor contains a calcium binding domain and two fluorescent reporter 
proteins with overlapping wavelengths, in this case CFP and YFP. (B) Upon binding of Ca2+ ions, the lower-
wavelength (donor) fluorophore transfers energy to its higher-wavelength neighbouring (acceptor) 
fluorophore, leading to an increased emission of photons by the acceptor. 
 
Troponin C (TnC) from skeletal and cardiac muscle appears to be a decent compromise: 
whereas it is a protein that folds and works at 37 °C - and hence in the rodent brain - it does 
not show any other functions other than to induce muscle contraction. In all of the animal 
kingdom, it can be found in many different variants showing diverse binding properties. 
Deriving it from a phylogenetically distinct species could even better rule out any undesirable 
interactions in the target organisms (Mank and Griesbeck, 2008). Griesbeck and colleagues 
have created an entire new family of GECIs by fusing variants and parts of skeletal and cardiac 
muscle Troponin C (TnC) with bioengineered variants of GFP (Garaschuk et al., 2007; Heim 
et al., 2007; Mank et al., 2006; 2008). The first sensor constructs were based on chicken skeletal 
muscle TnC (TN-L15) and human cardiac muscle TnC (TN-humTnC). To yield a brighter 
and better sensor, further engineering work produced CerTN-L15 and the intermediate 
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affinity sensor TN-XL. The Ca2+ binding domain mainly influences the sensor’s binding 
affinity and kinetics, whereas the signal intensity and the ratio change are strongly dependent 
on the fluorophore variants used. The dissociation constant (Kd) is an affinity measure and 
represents the concentration where 50% of the sensor protein is Ca2+ bound. It therefore 
provides a clue about the range of calcium concentrations it is able to detect. The maximal 
fractional ratio change (ΔR/R) is a measure of the amplitude of the calcium signal, dividing 
the maximal change in ratio (ΔR) by the baseline ratio. Table 1 compares selected TnC based 
biosensors with the specifications mentioned above. 
Indicator Binding moiety Donor  
fluorophore 
Acceptor 
fluorophore 
max ΔR/R  Kd Reference 
       
TN-L15 csTnC Δ14 eCFP Citrine 140 % 1.2 µM 
(Heim and Griesbeck, 
2004) 
CerTN-L15 csTnC Δ14 Cerulean Citrine 95 % 1.2 µM (Heim et al., 2007) 
TN-XL csTnC Δ14 eCFP Citrine cp174 400 % 2.5 µM (Mank et al., 2006) 
TN-XXL C-csTnC / C-csTnC eCFP Citrine cp174 230 % 0.8 µM (Mank et al., 2008) 
 
Table 1  Selected Troponin C based calcium sensors 
Selection of Troponin C based calcium sensors and their composition. csTnC: chicken skeletal Troponin 
C, ΔR/R max: maximum fractional Ratio change in experiments, Kd : dissociation constant. 
The combination of the genetic tools used to label neuronal subsets (as described in 1.3.1) and 
the bioengineered construction of a GECI yielded the creation of the Thy1-CerTN-L15 and 
Thy1-TN-XXL mouse lines. These transgenic strains strongly express the fluorescent 
indicator protein in neurons and their processes in many regions of the brain and spinal cord, 
making it possible to image axonal calcium dynamics in vivo, as performed in this study. 
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2. Objectives 
Axonal degeneration appears in a focal manner in inflammatory CNS lesions. The exact 
mechanisms of axon damage and its relation to infiltrating immune cells has so far remained 
elusive. Amongst potential mediators of this process, Ca2+ has been proposed to be a major 
player. However, so far no study has provided an in-depth analysis of axonal Ca2+ in actively 
induced models of EAE and characterized its impact on the pathway leading to focal axonal 
degeneration. This study aims to characterize axonal Ca2+ concentrations in 
neuroinflammatory lesions of the spinal cord and assess the influence of Ca2+ on the fate of the 
axon. Specifically, this work aims to answer the following questions: 
• Is there a modality to measure intracellular Ca2+ of single axons in vivo in the 
spinal cord? 
• Which imaging settings are needed to provide a valid and reliable readout of Ca2+ 
concentrations? 
• What is the baseline level of Ca2+ in healthy axons and can Ca2+ elevations be 
detected  under control conditions? 
• Can changes in intra-axonal Ca2+ be detected in lesions of acute EAE and at later 
timepoints (remission)? 
• If there appears to be a population of axons with elevated Ca2+, how does this 
influence their fate to subsequently undergo a process of degeneration? 
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3. Material and Methods 
3.1 Material list 
Reagents 
 
Surgery 
Agarose  Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany 
Bepanthen Augen- und Nasensalbe 5 g 
(eye ointment) 
 Bayer Vital GmbH, Leverkusen, Germany 
Cutasept F Lösung 250 ml 
(disinfectant spray) 
 Bode Chemie GmbH & Co, Hamburg, Germany 
Ethanol 70%  CLN GmbH, 
85416 Niederhummel, Germany  
Forene (Isoflurane)  Abbott AG, Baar, Switzerland 
Hydrogen Peroxide Solution (H2O2)  Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany 
Ketamine hydrochloride 10% 
(Ketamine) 
 Bremer Pharma GmbH, Warburg, Germany 
Ringerlösung Fresenius KabiPac 
(Ringer’s solution) 
 Fresenius KaBI Dtl., Bad Homburg, Germany 
Sterile artificial mouse cerebrospinal 
fluid (aCSF) 
 Solution A: 
8,66 g NaCl (Merck) 
0,224 g KCl (Merck) 
0,206 g CaCl2 · 2H2O (Sigma-Aldrich) 
0,163 g MgCl2 · 6H2O (Sigma-Aldrich) 
 
Solution B:  
0,214 g Na2HPO4 · 7H2O (Merck) 
0,027 g NaH2PO4 · H2O (Merck) 
dH20 ad 500 ml  
 
Mixture of solutions A and B in a 1:1 ratio  
 
Xylariem 20 mg (Xylazine)  Riemser Arzneimittel AG, Greifswald-Insel 
Riems, Germany 
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Tissue processing/ immunohistochemistry 
Phosphate Buffer (PB) 0,2 M   27,598 g NaH2PO4· H2O, 
35,598 g Na2 HPO4· 2H2O 
dH2O ad 1l 
Gibco Goat Serum  Invitrogen GmbH, Darmstadt, Germany 
Goat-anti-rabbit 594 antibody  Jackson ImmunoResearch Laboratories, 
West Grove (Pennsylvania), USA 
PFA (paraformaldehyde) 4%  8% PFA (Sigma-Aldrich) in dH2O, heated up 
to 55 °C and stirred additional 10 min, 
filtrated and mixed in a 1:1 ratio with 0,2 M 
PB (Phosphate buffer), pH adjusted to 7,2- 
7,8 
Phosphate Buffered Saline (PBS), 10x  103,23 mg Na2HPO4 · H2O 
26,52g Na2HPO4 · 2H2O 
40g NaCl 
H2O bidest. added to 1l 
Prepared in house. 
Polyclonal Rabbit Anti-Human Myelin 
Basic Protein 
 Dako/Agilent Technologies, Santa Clara , 
California, USA 
Sucrose  Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany 
TBS 10x (Tris buffered saline), pH=7,6  61 g Tris base (121,14 g/mol), (Sigma- 
Aldrich) 
90 g NaCl 
dH2O ad 1l 
Tissue Tek optimal cutting 
temperature 
(O.C.T.) 
 Sakura Finetek Europe B.V. , Alphen aan den 
Rijn, The Netherlands 
Triton X-100  Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany 
Vectashield Mounting Medium, 
Fluorescence H-1000 
 Vector Labs, Burlingame, CA 94010, USA 
   
Immunization 
Myelin Oligodendrocyte Glycoprotein 
(MOG)  
 Stock solution, produced by laboratory of Doron 
Merkler (Universität Göttingen, University of 
Geneva) 
M. tuberculosis H37 RA  Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany 
Incomplete Freund Adjuvans (IFA)  Sigma-Aldrich® Chemie GmbH, 82024 
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Taufkirchen, Germany 
Pertussistoxin (Ptx) from Bordetella 
pertussis, inactivated 
 Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany 
   
   
Tools and materials 
 
Surgical tools and materials 
Wella contura W7807 (Hair clipper)  Wella, Darmstadt, Germany 
Syringe 3pc 5 ml OmnifixTM luer slip 
(syringe for injection of Ringer’s 
solution) 
 
 B. Braun Melsungen AG, Melsungen, Germany  
 
BD Plastipak Hypodermic luer slip 
syringe 1 ml (syringe for 
Ketamine/Xylazine and Ptx injection )  
 Becton, Dickinson and Company, Franklin Lakes 
(New Jersey), USA  
 
Feather stainless steel blade (surgical 
blade)  
 pfm medical ag, Cologne, Germany  
 
Noyes Spring Scissors (Large spring 
scissors)  
 
 Fine Science Tools GmbH, Heidelberg, Germany  
Vannas-Tübingen Spring Scissors 
(Small angled spring scissors) 
 Fine Science Tools GmbH, Heidelberg, Germany  
Dumont Mini Forceps – Inox Style 3 
(Small forceps) 
 Fine Science Tools GmbH, Heidelberg, Germany  
Dumont Mini Forceps – Inox Style 5 
(Small forceps, smaller tip than Inox 
style 3) 
 Fine Science Tools GmbH, Heidelberg, Germany  
Hypodermic Needles BD Microlance 3 
30 Gauge (0,3 mm, yellow) for 
subcutaneous injection of Ringer’s 
solution and anesthesia 
 Becton, Dickinson and Company, Franklin Lakes 
(New Jersey), USA 
Hypodermic Needles BD Microlance 
3 23 Gauge (0,6 mm, blue) for 
subcutaneous emulsion immunization 
 Becton, Dickinson and Company, Franklin Lakes 
(New Jersey), USA 
Ethicon Ethilon monofil 6-0 size, 
667H (skin suture) 
 Johnson & Johnson Medical GmbH, Norderstedt, 
Germany 
Ethicon Vicryl 4-0 size, MIC101H 
(intracorporal suture) 
 Johnson & Johnson Medical GmbH, Norderstedt, 
Germany 
Sugi (absorbent triangles)   Kettenbach GmbH & Co. KG, Eschenburg, 
Germany 
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Metal plate  Custom-made 
Cast Alnico Button Magnets  Eclipse Magnetics Ltd, Sheffield, UK 
Rubber bands   
Support cushion  Custom-made 
Osmotic minipump (Model 1007B)  Alzet, Cupertino (California), USA 
Intrathecal catheter (Model 7743)  Alzet, Cupertino (California), USA 
   
Tools and materials for histology   
Microscope slides 76x26 mm  Gerhard Menzel Glasbearbeitungswerk 
GmbH & Co. KG, Braunschweig, Germany 
Microscope cover slips 24x60 mm  Gerhard Menzel Glasbearbeitungswerk 
GmbH & Co. KG, Braunschweig, Germany 
Parafilm  Brand GmbH & Co. KG, Wertheim 
Germany 
Pipettes, pipette tips and tubes (2ml 
and 1,5 
ml) 
 Eppendorf AG, Hamburg, Germany 
12-well cell culture plates  Becton, Dickinson and Company, Franklin 
Lakes (New Jersey), USA 
Tissue Tek Cryomold Standard, 
25x20x5 mm 
 Sakura Finetek Europe B.V. , Alphen aan den 
Rijn, The Netherlands 
Tissue Tek Cryomold Biopsy, 10x10x5 
mm 
 Sakura Finetek Europe B.V. , Alphen aan den 
Rijn, The Netherlands 
Paper filters (185 mm Ø circles)  Whatman Schleicher & Schuell GmbH, 
Dassel, Germany 
50 ml centrifuge tubes  Greiner Bio-One GmbH, Frickenhausen, 
Germany 
   
   
Technical devices 
 
Surgery  
Olympus KL 1500 LCD (cold light 
source for stereomicroscopy) 
 Olympus Deutschland GmbH, Hamburg, 
Germany 
Olympus Stereo Microscope SZ51  Olympus Deutschland GmbH, Hamburg, 
Germany 
FST 250 Hot Bead Sterilizer (sterilizer 
for surgical instruments) 
 Fine Science Tools GmbH, Heidelberg, Germany 
T/Pump (Heating pad)  Gaymar Industries, Orchard Park (New York), 
USA 
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Histology   
Leica CM1850 cryostat  Leica Microsystems GmbH, Wetzlar, 
Germany 
Vibratome 1000Plus  Intracel LTD, Shepreth, Royston, 
Great Britain 
Vortex-Genie 2  Scientific Industries, Inc., Bohemia (New 
York), USA 
KERN EW 150-3M (scales)  Kern & Sohn GmbH, Balingen-Frommern, 
Germany 
Laboratory pH meter inoLAB  WTW Wissenschaftlich-Technische 
Werkstätten, Weilheim, Germany 
Magnetic stirring hotplate MR 3001K 
and stirring bars 
 Heidolph Instruments GmBH & Co. KG, 
Schwabach, Germany 
Ismatec IP high precision 
multichannel pump 
(pump for perfusions) 
 ISMATEC SA, Labortechnik - Analytik, 
Glattbrugg, Switzerland 
Olympus IX71 inverted fluorescence 
microscope (evaluation of 
immunohistochemistry) 
 Olympus GmbH, Hamburg, Germany 
   
Microscopy   
FV1000 confocal system mounted on 
an 
upright BX61 microscope, equipped 
with an 
x10/0.4 water immersion objective and 
x20/0.85 and x60/1.42 oil immersion 
objectives (confocal microscopy) 
 Olympus GmbH, Hamburg, Germany 
Olympus FV1000 MPE multiphoton 
Microscope 
x25/1.05 water immersion objective 
 Olympus GmbH, Hamburg, Germany 
MaiTai eHP/HP Titanium:sapphire 
laser 
 Newport/ Spectraphysics, Irvine, California, USA 
Manual XY translation stage   Custom build, parts by Thorlabs Inc 
Newton (New Jersey), USA 
   
Data analysis/ Software   
Adobe Creative Suite (Photoshop, 
Illustrator) 
 Adobe Systems, Inc., San Jose, California, USA 
ImageJ/ FIJI  General Public License 
http://rsbweb.nih.gov/ij/download.html 
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Graphpad Prism  GraphPad Software, La Jolla, California, USA 
Microsoft Office (Powerpoint, Excel, 
Word) 
 Microsoft Corporation, Redmond, Washington, 
USA 
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3.2 Experimental animals 
All experimental mice were kept and bred in the animal facilities of the institution under 
standard conditions. Animals were held in Eurostandard Type II long cages 365x207x140 
mmH (Tecniplast, Hohenpreißenberg, Germany) stored in an IVC rack system with a 
maximum of five mice per cage. Autoclaved food (regular food “Maus” from Ssniff, Soest, 
Germany) and water were supplied ad libitum. Mice were held at a 12 h light/12 h dark cycle. 
The lines used included the transgene Thy1-CeTN-L15 as well as Thy1-TN-XXL, provided by 
O. Griesbeck (MPI for Neurobiology, Martinsried). Both lines were created on a FVB or a 
FVB: C57BL/6 background and express the corresponding GECI protein CerTN-L15 (Heim et 
al., 2007) and TN-XXL (Mank et al., 2008) under the neuronal expression cassette Thy-1.2. To 
assess fluorescence bleedthrough during imaging of these sensors, we used thy1-CFP23 and 
thy1-YFP-H lines, and a cross of both lines for the pH effect experiments. All animal work 
conformed to institutional guidelines and was approved by the Animal Study Committee of 
the Regierung von Oberbayern, reference 55.2-1-54-2532-9-10. 
 
3.3 Methods 
3.3.1 Experimental autoimmune encephalomyelitis (EAE) 
Experimental autoimmune encephalomyelitis was induced according to a standard 
protocol (Abdul-Majid et al., 2000). Adult mice were immunized (p42-p98) with 250 µl of an 
emulsion containing 200 µg purified recombinant myelin oligodendrocyte protein (MOG, 
N1-125, produced in E-coli) in complete Freunds adjuvant containing 625 µg Mycobacterium 
tuberculosis H37 Ra.  Each anesthetized animal (i.p. Ketamine 87 µg/g body weight, Xylazin 
13 µg/g body weight) received 3 subcutaneous injections of the emulsion: 100 µl each on both 
flanks and 50 µl at the base of the tail. On the day of immunization and 2 days later, 250 ng of 
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Pertussistoxin (Ptx) in 100 µl of sterile Saline was injected intraperitoneally. All immunized 
mice were weighed and scored daily according to a standardized clinical EAE scale reflecting 
neuronal deficits (see Table 2). 
 
Score Clinical signs 
0 No signs of disease 
0.5 Distal tail weakness 
1 Complete paralysis of the tail 
1.5 Minor hind limb weakness, gait ataxia 
2 Paresis of the hind limbs 
2.5 Paresis of the hind limbs, partial dragging of the feet 
3 Complete paralysis of the hind limbs 
3.5 Complete hind limb paralysis with weakness of the forelimbs 
4 Complete paralysis of the hind limbs and forelimbs 
5 Moribund 
Table 2  EAE clinical scoring scale 
 
3.3.2 Tissue processing and immunohistochemistry 
After lethal anaesthesia with isofluorane, animals were perfused transcardially with 10 ml 
of saline solution followed by 30 ml of 4% paraformaldehyde (PFA) in 0.1 M phosphate 
buffer. The vertebral column was coarsely dissected and the tissue post-fixed in 4% PFA at  
4 °C for 24 h. After this, the tissue was transferred for storage to PBS, until the lumbar spinal 
cord was dissected under the stereomicroscope. For consecutive immunofluorescence 
analysis, spinal cords were cryoprotected in 30% sucrose for at least 24 h at 4 °C until the 
tissue density equilibrated with that of the sucrose solution. To prepare cutting the specimen 
was embedded in Tissue-Tek optimal cutting temperature (O.C.T.) compound and frozen at -
20 °C. 40-60 μm thick transversal sections were cut on a freezing microtome, collected in well 
plates containing PBS and subsequently processed for immunohistochemistry. Myelin Basic 
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Protein (MBP) staining was done using the protocol outlined in Table 3. Neurotrace staining 
was performed as step 7, in a 1:500 dilution. 
Step Temperature Time Medium 
1 Room temperature 
(RT) 
3 x 10 min PBS 
2 -20 °C 15 min Methanol 
3 RT 3 x 15 min PBS 
4 RT 60 min 10 % goat serum (GS) in 0.5 % TrisPBS 
5 4 °C 12 – 24 h Rabbit-anti-human MBP 1:200 in 1 % GS in 
TrisPBS 
6 RT 3 x 15 min PBS 
7 4 °C 12 – 24 h AlexaFluor 594 goat-anti-rabbit 1:500 in 1 % 
GS + TrisPBS 
8 RT 3 x 30 min PBS 
Table 3  Staining protocol Myelin Basic Protein (MBP) 
After staining, tissue sections were mounted on glass slides with vectashield and 
coverslipped using a magnifying glass or stereomicroscope.  
3.3.3 Confocal microscopy 
Fixed tissue samples were scanned on a FV1000 confocal system mounted on an upright 
BX61 microscope stand (Olympus). The system was equipped with a 10x/0.4 water immersion 
objective, 20x/0.85 and 60x/1.42 oil immersion objectives. Recorded 12-bit image stacks were 
subsequently processed using ImageJ (http://rsbweb.nih.gov/ij) or Adobe Photoshop software. 
3.3.4 Surgery procedures 
3.3.4.1 In-vivo imaging preparation 
All surgery procedures were done according to previously established protocols 
(Kerschensteiner et al., 2005; Misgeld et al., 2007a). Mice were intraperitoneally anaesthetized 
with ketamine-xylazine (ketamine 87 μg per g body weight, xylazine 13 μg per g body weight) 
and transferred to a heating pad for approximately 15-30 min to ensure deep anaesthesia. The 
fur above the lumbar spinal cord was shaved. To achieve good access to the intervertebral 
space, animals were positioned on a metal plate with limbs outstretched, with the head and 
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neck supported using  a cushion. 70 % ethanol was used to wipe the exposed skin 4-5 times for 
cleaning and disinfection. A median incision of the skin above the lumbar vertebrae was 
performed using a scalp blade and the subcutaneous space was prepared with spring scissors. 
Lateral to the vertebral column, an incision of the muscle on both sides was made and the 
intervertebral space was opened by applying tension to the median muscular string and 
carefully cutting through the musculature. Any bleeding that occurred was staunched with 
sterile cotton swabs (Sugi). Once the spinal cord, covered by the dura mater, became visible, 
two vertebral laminae, along with the attached muscular tissue were removed by laminectomy 
with 14mm angled-blade spring scissors. The preparation was occasionally rinsed with aCSF 
to keep it clean and moist. To immobilize the spinal cord and reduce breathing artefacts, the 
vertebrae adjacent to the opening were clamped with a specifically engineered clamping 
device (Narishige STS-A) and equally fixed the tail of the animal. To keep the exposed area 
continuously moist, and to achieve a stable level of the immersion liquid, an imaging well with 
2% Agarose was created that fitted the geometry of the objective, and filled it with an aCSF 
bath. For long-term experiments, the solution was preheated (37 °C) and superfused across 
the well. 
3.3.4.2 Implantation of osmotic mini pumps 
For bepridil treatment experiments, animals were implanted with an osmotic mini pump 
(Alzet) delivering 0.41mM bepridil in 0.5 % DMSO containing saline or vehicle (0.5 % DMSO 
in saline) through an intraspinal catheter. Pumps yielded a total capacity of approximately 100 
µl and an average output of 12 µl per day. Each pump was weighed before and after filling to 
validate proper loading and only filled on the day of surgery. Implantation was scheduled for 
the clinical onset of disease, with a score-matched distribution of vehicle and treatment 
groups. Surgery was performed with the guidance and assistance of I. Nikic. The 
intervertebral space was accessed and opened in the caudal lumbar vertebral column. The 
intraspinal catheter was attached to the pre-incubated pump and inserted into the intrathecal 
space, pointing caudally to rule out trauma to the spinal cord. For fixation, we sutured the 
catheter to the vertebral muscles and attached the pump in such a way that it rested in the 
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subcutaneous space and therefore kept its working temperature. The skin was sutured and the 
mouse was rehydrated with 1 ml of s.c. injected Ringer’s solution before placement into the 
heated wake-up station. After 3 days of treatment, animals were perfused as described in 3.3.2 
and the residual volume and weight of the pumps was assessed to evaluate the success of 
delivery. 
3.3.5 2-Photon in vivo imaging 
For in vivo microscopy, a FV1000MPE system was used (Olympus), consisting of a 
FV1000MPE scan unit with a spectrally tuneable Titanium:sapphire laser (Spectra 
Physics/Newport) emitting femtosecond pulses of near-infrared light. Coupling of the 
lightpath and IR-laser modulation was achieved via an acousto-optic modulator or a 
transmission filter (AOM, AOTF) and beam size was adjusted via a keplerian beam expander. 
The microscope stand was a BX61WI (Olympus) upright microscope with motorized 
nosepiece focusdrive, together with a custom built, manual stage (using parts from Thor Labs) 
or a motorized InVivo bridge (Luigs-Neumann). For all experiments including CerTN-L15 
mice an excitation wavelength of 840 nm was used together with emission filter systems 
collecting 460-510 nm for the Cerulean channel and 515-560 for eYFP or FRET channel. The 
two corresponding detectors were non-descanned detector photomultiplier tubes (PMTs, 
Hamamatsu) or gallium arsenide phosphide (GaAsP) detectors. All experiments were done 
with a 25x/1.05w dipping cone objective (Olympus) immersed in aCSF. Images were acquired 
using Olympus Fluoview 1000 software. Animals were kept under constant anaesthesia with 
checks for breathing and reflexes at 30 min intervals. During periods when animals were not 
being imaged,  their body temperature was regulated by radiation with an infrared lamp. 
The timecontroller function of the Fluoview software enabled repeated acquisition of 
high-resolution overviews of the spinal cord by imaging a predefined matrix of regions using a 
zoom of 2-3x over a timecourse of several hours, yielding a 400-500 µm imaging field with a 
pixel size of ≈400 nm. If movement-induced drift in the z-plane of the image was detected 
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during the experiment, the centre of the image stack was adjusted uninterruptedly to the 
correct position. 
3.3.6 Data analysis 
Data was processed and analysed using FIJI, a version of ImageJ optimized for life science 
applications (http://fiji.sc/Fiji), and Adobe Photoshop. Recorded images were loaded into the 
FIJI software using the Bioformats Importer plugin. For the evaluation of ratiometric images, 
the two separate channels that constituted each complete image were opened. Three regions 
of interest (ROI) were then drawn in the axons and background areas respectively of the first 
image, and then identically copied onto the second channel. The integrated fluorescence 
intensities within the corresponding ROIs were then measured from each channel (see Figure 
6).  
 
Figure 6  Measuring regions of interest (ROIs) for single axons and nearby background 
Clipped part of YFP channel in raw image data stack. ROI 1-3 (yellow selections) were selected in the 
axaplasm, ROI 4-6 in nearby background. The measurements include area of ROIs (in µm²), mean grey value 
and SD (StdDev), Minimal (Min) and Maximal (Max) grey values and position in Z-stack (Slice). 
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The formulas applied to the measurements are depicted below. Note: To simplify 
terminology, CFP refers to blue fluorescent proteins in general and YFP for yellow fluorescent 
proteins. The abbreviations therefore include fluorophore variants like Cerulean or circularly 
permuted (cp) modifications. 
RATIO = (FRETInt – FRETBKGND) / (CFPInt – CFPBKGND) 
FRETInt = YFPInt - BF x CFPInt ;  FRETBKGND = YFPBKGND - BF x CFPBKGND 
Formula 1  FRET Ratio calculated from the signal and background of the two channels 
FRETInt and CFPInt represent the intensity of the FRET and CFP channels in the ROI, and 
FRETBKGND and CFPBKGND represent the intensity of FRET and CFP in the background ROI. 
The original data from the YFP channel (YFPInt , YFPBKGND) was before corrected for spectral 
bleedthrough with an experimentally derived bleedthrough factor (BF), as shown in chapter 
4.2. All grey values presented as an arbitrary unit in 12-bit images, with values ranging from 0-
4095 (=212). 
To get a coarse impression of the ratiometric state, and therefore Ca2+ level of an axon, the 
CFP channel represented by a red look-up-table (LUT), and the FRET channel coded in a 
green LUT, were merged. This yielded an image where a green-shifted structure would imply 
high Ca2+ levels. Truly ratiometric images were created using the following procedure: 
maximum intensity projections of single channels were background corrected by using the 
thresholding tool on the channel with a higher signal-to-noise ratio.  This ‘mask’ was then 
applied to both channels to exclude signal from background structures. By using the image 
calculator, the resulting, masked images of both channels (FRET/CFP) were divided to yield a 
greyscale, 32-bit float image also handling pixels divided by a custom look-up-table (LUT) 
derived from the “Fire LUT” (representing the highest ratios as yellow and lower ratios as 
violet to black) was applied.  A ‘despeckle filter’ was applied to the original grey-scale image 
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projection from the FRET channel, and the intensity of the resultant image was then adjusted 
in Photoshop. The derived ratiometric RGB images were blended with the grey-scale image 
using the “Color” option to yield an image that represents the grey-scale as a function of 
intensity and the modified fire LUT as a function of FRET ratio. 
To create large area timelapse videos, the single tile images were z-projected using the 
“maximum intensity projection” function in FIJI, stitched together via the semiautomatic 
merge tool in Photoshop and registered to the other timepoints by the “register virtual stack 
slices” plugin in FIJI. 
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4. Results 
4.1 Characterization of GECI transgenic animals 
To find out whether I would be able to detect calcium signals in vivo, I first studied the 
baseline fluorescent signal of the transgenic animals we received from the group of O. 
Griesbeck (s. chapters 1.3.2 and 3.2). Both lines, thy1-CerTN-L15 as well as thy1-TN-XXL, 
contain a blue and a yellow fluorescent protein variant and could be excited with a wavelength 
840 nm of a femto-second pulsed laser beam. The dissimilarities in the fluorophores attached 
to the sensor backbone of the two sensor proteins (s. Table 1) and/or the expression levels 
yielded a difference in baseline brightness as seen in Figure 7.  
 
Figure 7  In vivo signal of thy1-CerTN-L15 and thy1-TN-XXL 
Projection images showing the in vivo CFP signal of both GECI lines in the lumbar spinal cord, imaged 
under the 2-photon microscope. Axonal signal differs in brightness, here color-coded by the “cyan-hot” 
look-up-table shown in the scale on the right. Asterisk (right) highlights a blood vessel. Both images were 
scanned with the same detector settings and AOTF transmission of 5% (left) and 6 % (right). Scale bar: 50 
µm. 
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As depicted in Figure 7, both lines provide a dense labelling pattern of axons with the 
GECIs. However, identification of a single axon and tracing it over up to hundreds of 
micrometres remains possible.  
 
Figure 8  Analysis of axon populations of the GECI lines. 
(A)(C) Single plane confocal image showing a transverse section of the lumbar spinal cord of a thy1-
CerTN-L15 and thy1-TN-XXL transgenic immunostained for myelin basic protein (MBP, white). Scale bars 
= 5 µm. (B) (D) Axon diameter distribution plotted as frequencies in 0.25 µm bins. Analysed in-situ on MBP 
immunostained spinal cord transverse sections for CerTN and in vivo for TNXXL. Box: Quantification of 
MBP ensheathement in thin (<1 μm) and thick (≥1 μm) caliber axons in TNXXL (179 axons, 2 mice). (C) and 
(D) taken and modified from Williams et al., 2014.  
There is a visible and measurable difference in the size of the axons labelled in the lumbar 
spinal cord. Whereas thy1-TN-XXL labels mostly axons that are below 1 µm in diameter, the 
normal distribution of labelled axon diameters in thy1-CerTN-L15 centres around a mean of 
2.16 µm (SD: 0.98 µm). I decided to do all experiments with the thy1-CerTN-L15 mouse strain 
Results 
 
39 
because of two reasons: First, the wider distribution of axon sizes. This allows the 
morphological assessment of small calibre as well as intermediate and larger calibre axons. 
Second, the brighter presentation of the fluorescent sensor proteins. All of the following 
experiments where thus done on thy1-CerTN-L15 animals, which I will refer to as “CerTN” in 
the following chapters. 
4.2 Interpretation of ratiometric calcium indicator signals 
4.2.1 Imaging settings and bleedthrough correction 
As the ratiometric signal is interpreted as a direct correlate of intracellular calcium 
concentration (see chapter 1.3.2), I aimed to improve my imaging approach so that I can 
detect the FRET changes as close as possible to their full extent. The two main factors to 
influence this are 1.) an optimized signal-to-noise ratio and 2.) correction for spectral overlap 
of the channels, also known as “bleedthrough” or “crosstalk”. First, I measured signal-to-noise 
(S/N) for different excitation and detection settings, to yield optimized imaging parameters 
that I could use for the rest of the experiments. In Figure 9, S/N values are plotted separately 
for both the CFP and the YFP channel, with different PMT detector voltages on the abscissa 
and using incremental laser power (shown by symbols). The best compromise of decent S/N, 
while using “as-little-as-possible” laser intensities turned out to be the settings shown in Table 
4. I established these imaging settings as the optimized setup for all experiments. 
 One major confounder in the detection of simultaneous fluorescent channels is spectral 
overlap. This phenomenon describes the imperfect separation of fluorophores with 
overlapping spectra in the recorded channels of a fluorescent microscope. The means to 
correct for this, spectral unmixing, is described in the literature (Zal and Gascoigne, 2004). In 
my experiments, I imaged transgenic animals expressing CFP only (thy1-CFP-23 line) and 
YFP only (thy1-YFP16), sequentially under the same conditions and settings like CerTN. I 
saw no channel crosstalk appearing in the CFP channel when exciting YFP. When imaging the 
CFP sample, I detected signal in the YFP channel that yielded 22 % of the signal in the CFP 
Results 
 
40 
channel. The calculated bleedthrough factor (BF) of  0.22 was from then on applied to all grey 
values measured in the YFP channel (see formula p. 35). 
 
Figure 9  Signal-to-noise plot for different excitation detection parameters 
Parameter  Value 
Objective  25x / 1.05w 
Zoom / Pixel number  3 / 512x512 
Laser power out / AOTF Transmission  ≅2.5 W / 5-8 % 
Barrier filters  Channel 1: 
Channel 2: 
460 - 510 nm 
515 - 560 nm 
PMT voltage Channel 1: 
Channel 2: 
600 V 
600 V 
PMT gain Channel 1: 
Channel 2: 
1 
1 
PMT offset Channel 1: 
Channel 2: 
4 
4 
Table 4  Determined optimal imaging settings for constant application 
All parameters defined in this table were kept constant to make measured FRET ratios reliable and 
consistent. Laser power transmission had to be adapted according to preparation quality but did not change 
overall ratio.  
4.2.2 Baseline ratiometric signal and positive controls 
To get a thorough understanding of the baseline ratios that spinal axons show in control 
animals, I imaged healthy CerTN transgenic mice and evaluated a total of 173 axons (3 
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animals) as described in chapter 3.3.6. The baseline YFP/CFP ratios are shown in Figure 10. 
Ratios are normally distributed with a mean value of 0.193 (SD = 0.028). To rule out any 
correlation with axon calibre (e.g. due to differences in sensor concentration and buffering 
capacities), values are plotted over the diameter of the measured axons. The even distribution 
does not suggest any correlation (Pearson r= -0.02). I also could not detect a correlation of 
YFP/CFP ratio and labelling intensity as shown by the graph in Figure 10.  
Extracellular Ca2+ is known to enter axons when they are transsected. I used this principle 
as a positive control to assess if I can detect a ratio change in axons that had been 
mechanically transsected in a spinal cord injury paradigm. On 2 days and 4 days post injury, I 
detected elevated YFP/CFP ratios in axons with different morphology, but mostly in axon 
fragments. Measured ratios are shown in Figure 10 and turned out to show an almost 3-fold 
increase of the mean control value (maximum value: 0.55, mean control: 0.19). This strongly 
suggests a clear readout of elevated calcium levels. These findings presented preliminary data 
for ongoing studies in two different disease paradigms. First, in the setting of EAE as 
presented in this work here. Second, in a model of spinal cord contusion, as shown in our 
corresponding publication (Williams et al., 2014). 
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Figure 10  Baseline signal and ratios in healthy animals and positive control after spinal cord cut. 
(A)  YFP and CFP channel intensity scatter plot of single axons. The values are evenly distributed and 
signal intensities do not correlate with YFP/CFP ratio (B) Axonal calcium levels, as represented by YFP/CFP 
ratios are strongly regulated in control animals and show no correlation with axon diameters. (B) In a spinal 
cord injury paradigm, elevated calcium levels can be detected in a subset of axons 2d and 4d post injury.  
4.3 Axonal calcium levels in acute EAE  
My next step was to look at the lumbar spinal cord of a mouse in the acute phase of EAE. 
Using our in vivo imaging approach I could detect axons that showed increased YFP/CFP 
ratios and therefore elevated axonal calcium.  Figure 11 shows the appearance of an inflamed 
spinal cord in EAE. Infiltrating immune cells appear in such lesion sites. Such sites can be 
identified in vivo based on the presence of morphologically altered axons in different stages of 
focal axonal degeneration (Nikić et al., 2011).  I quantified the changes in axonal calcium and 
morphology, using the three different stages that our laboratory has shown to be sequential 
steps of a partly reversible degeneration process. For a robust readout of the calcium sensor, I 
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defined the control mean +3 SD as the cut-off value for YFP/CFP ratios that indicate elevated 
axonal calcium.  As seen in the spinal cord cut paradigm (see chapter 4.2.2), many axonal 
fragments tend to show high calcium. Notably, in EAE I could detect that roughly half of the 
stage 1 axons (axonal swellings without fragmentation) and 16 % of the “normal” appearing  
stage 0 axons have increased Ca2+ levels. The ratio changes appear to be up to 4-fold and vary 
in their extent. The calculated ratios (normalized to the control population) were 1.25 ± 0.05 
in stage 0, 1.81 ± 0.11 in stage1 and 2.15 ± 0.09 in stage 2 axons (mean ± SEM). 
I observed the calcium elevations to affect the whole stretch of the axon length that I was 
able to detect in my imaging approach.  These changes are consistent with the idea that Ca2+  
is a mediator of axonal degeneration under neuroinflammatory conditions. To rule out any 
influence of acidosis or pH in general on the relative fluorescence of the two fluorophores 
incorporated in the sensor protein, I crossed thy1-CFP23 with thy1-YFP16 animals. The 
crossing of two lines with almost full labelling patterns would provide a majority of axons that 
show double labelling with a blue and a yellow fluorescent protein as integrated in the FRET 
sensor of CerTN. Differential pH effects on these two XFP variants could explain a ratio 
change, especially as there is evidence for tissue acidosis in the EAE spinal cord (Friese et al., 
2007). However, in our experiments we could not observe any change in axon ratio that would 
resemble the strong signal we see in axons with a functional FRET-based calcium sensor, as 
shown in Figure 12.  Axon ratios presented with values centering around the control mean 
(stage 0: 0.99 ± 0.02, stage 1: 1.01 ± 0.05, stage 2: 1.27 ± 0.13, mean ± SEM). 
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Figure 11  Axonal calcium levels in acute EAE 
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(A) 2-Photon in vivo image of the lumbar spinal cord of a control animal and an animal suffering EAE 
(onset +2d).  Greyscale images show CerTN YFP channel in maximum intensity projection. Ratiometric 
images depict color-coded calcium levels, ranging from low (blue/violet) to high calcium (yellow), as 
shown in look-up table scale. Scale bar 20 µm. (B) Stages of focal axonal degeneration taken from images 
in (A) showing a normal appearing (0), swollen (1) and fragmented (2) axons. (C) Axonal calcium levels 
in acute EAE lesions, shown by YFP/CFP ratios normalized to control group. Color-coded cut-off marks 
an increase of +3 SD above the control mean, defined in this study as elevated calcium. Percentages 
represent the number of axons that show elevated calcium, grouped in the different stages of 
degeneration. Control: n=3 animals, EAE n=5 animals. 
 
Figure 12 Effects of pH on fluorophores in acute EAE 
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(A) Representative ratiometric images showing spinal cord axons in CFP23xYFP16 control mice and 
animals suffering acute EAE.  No effect is seen mimicking the measured change in ratio as observed in 
CerTN mice.  
4.4 Axonal calcium levels in EAE remission 
To correlate these findings with lesion activity, I imaged animals which presented 
themselves in the remission phase of EAE (onset+10 d, onset +12 d) as shown in Figure 13. 
Similar to the acute lesions, I could detect morphological changes of axon populations and 
elevated intra-axonal calcium. However, the changes were shifted to the later phase of 
degeneration (stage 2, 1.81 ± 0.09) and less of the morphologically intact (stage 0: 0.92 ± 0.03) 
axons affected. Swollen axons (stage 1) showed also a lower mean ratio than in the acute 
situation (1.37 ± 0.25, mean ± SEM). This points towards the presentation of a “burnt-out” 
lesion with less activity.  
 
Figure 13  Axonal calcium levels in EAE remission 
Axonal calcium levels in remitting EAE lesions (onset +10d, +12d), shown by YFP/CFP ratios 
normalized to the control group. Percentages represent the number of axons that show elevated calcium per 
stage of degeneration. Control: n=3 animals, EAE n=3 animals.  
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4.5 Fate mapping of affected axonal populations over time 
Since I discovered that elevated calcium levels appear in intact looking axons and this 
could be observed more frequently in the setting of acute EAE compared to the remission 
phase (see Figure 11 and Figure 13), I became interested in the timecourse of calcium influx 
and the correlated appearance of morphological changes. To follow axonal calcium dynamics 
in vivo, I imaged animals for 3-5 h in 30-45 min intervals. To exclude that changes seen in 
imaged axons are due to surgery-induced trauma and/or phototoxicity, I imaged control 
animals over the same timecourse and did not detect any changes in axonal calcium or 
morphology, as shown in Figure 14.  
 
Figure 14  Control timelapse imaging 
(A) Ratiometric projection images of representative region in a healthy control animal at t=0 and t=180 
min. Minor variation due to breathing artefacts. (B) Quantification of YFP/CFP axon ratios of a cohort of 
axons at t=0 and t=180 min. Values normalized to t=0.  
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I then classified axonal morphology changes over time into the different stages of FAD. As 
plotted in Figure 15 (A), I could detect an overall constant rate of fragmenting axons (stage 2, 
red) between the different timepoints that did not occur in a time-locked manner as one 
would expect e.g. in trauma-induced degeneration. When specifying which transitions occur 
among morphological stages and between the states of Ca2+ high and Ca2+low, all types could 
be detected. To evaluate the frequencies of the observed transitions I followed a cohort of 277 
axons over time. I plotted the pooled transition probabilities averaged over time in the 
diagram shown in Figure 15 (C). As depicted in the transition diagram, the per hour 
probability for an axon to undergo subsequent degeneration is higher for entities with 
elevated Ca2+ than for neighboring axons without an intracellular calcium increase. This 
applies both to morphologically intact as well as swollen axons. Interestingly, axons can also 
recover high Ca2+ and morphological swellings. The chances to do the latter are higher for low 
intra-axonal Ca2+. 
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Figure 15  Assessment of axonal cohort over time 
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(A) Distribution of FAD stages 0 (green), 1 (yellow) and 2 (red) in a population of axons followed over 
the course of 6 timepoints (t1 - t6, intervals 30-45 min). Irreversible stage 2 are presented as drop-out 
fractions. (B) Pseudocolored ratiometric images of single axons showing axonal morphology and calcium at 
different timepoints: Axon 1 (top) degenerates to a fragmented stage while showing high calcium 
throughout all images. Axon 2 (middle) recovers low calcium levels without shape changes. Axon 3 (bottom) 
shows low calcium levels and recovers from stage 1. (C) Diagram showing probabilities (per hour and axon) 
of a transition to occur. Symbols reflect FAD stages 0, 1 and 2 as shown in Figure 11. n=277 axons in 8 
animals. 
4.6.   Additional Figures  
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Figure 16  Effects of H2O2 on healthy spinal cord axons 
Ratiometric projection images of axons before and after incubation with 100mM H2O2 (30, 45 and 80 
min. respectively, incubation stopped for imaging periods). A clear rise of Ca2+ can be detected in a majority 
of axons with subsequent degeneration. Scale bar: 10 µm. 
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Figure 17  Effects of intrathecal treatment with bepridil in EAE 
Animals (thy1-YFP16xMitoP) showing weight loss just before the onset of clinical symptoms were 
implanted an osmotic mini pump containing 0.4 mM bepridil (n=7) or vehicle (n=6) in aCSF.  (A) Clinical 
scores of treated animals over the acute disease phase. Unpaired t-test (p=0.048) (B) Axon stages in 
inflammatory lesions were evaluated in fixed tissue sections. Lesions were classified by cellular infiltration 
(NeuroTrace staining). 
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5. Discussion 
5.1 In vivo calcium imaging: pitfalls and potentials 
5.1.1 Detection of calcium signals 
In this study I imaged axonal calcium levels in vivo in the murine spinal cord. The signal 
was collected by two-photon laser scanning microscopy of neurons expressing genetically 
encoded calcium indicator proteins. I was able to detect an increase in FRET ratios in diseased 
animals compared to a determined control baseline. The valid interpretation of this signal is 
of chief concern. For this we need to understand the functional principles and the correct 
readout of the received signals, as well as possible confounders.  
The underlying Ca2+-sensing mechanism of the CerTN protein is the FRET principle and 
the correct readout a change in the YFP/CFP channel ratio (see chapter 1.3.2). To calculate 
this ratio and optimize the signal strength, I corrected for background and bleedthrough (see 
chapters 3.3.6, 4.2.1).  This led to a very confined normal distribution of axon ratios when 
measured in healthy control animals, as seen in chapter 4.2.2.  
In the original description of the CerTNL15 sensor protein, Heim et al. used cortical and 
hippocampal slice preparations and in-vivo imaging in the murine cortex to assess the sensor 
protein’s behaviour upon stimulation. Slice cultures were incubated in a depolarizing solution 
(10 mM Ca2+ and 80 mM K+) to provoke a rise of FRET ratios. Single patch-clamped cells 
were stimulated with current injections or iontophoretic glutamate application. The 
subsequent membrane depolarization, verified by electrophysiology techniques, could be 
linked to an increase in FRET ratio and therefore calcium influx. In vivo measurements on 
spiny dendrites showed the same effect (Heim et al., 2007). 
In my positive control, transected axons in the traumatically injured spinal cord, I could 
detect FRET ratios that were up to 3-fold higher than the mean of the controls, but also 
intermediate stages could be seen. In the neuroinflammatory paradigm of EAE, I could detect 
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comparably high ratio changes in a population of the axons, with a majority of them showing 
morphological changes. Other groups have successfully measured Ca2+ elevations with a 
genetically encoded calcium indicator in vivo in different scenarios, e.g. in models of 
Alzheimer disease in the murine cortex (Kuchibhotla et al., 2008) and also in the inflamed 
brainstem of mice suffering a passive EAE variant (Siffrin et al., 2010).  
As the signal is highly probable to arise from calcium fluctuations, there still can be major 
confounders. First, for the healthy axon population, we confirmed that the ratiometric signal 
did not correlate with the size of the axon or the signal intensity and thus the expression level 
of the sensor protein (see Figure 10). Second, in the setting of neuroinflammatory lesions 
tissue acidosis has been described (Friese et al., 2007), which could disturb the function of the 
sensor protein. Yellow fluorescent proteins are known to be more affected by acid/base 
imbalances and will change their fluorescent properties accordingly. To rule out an effect due 
to differential pH effects on the fluorescent reporter proteins forming the calcium sensor, we 
expressed both fluorescent proteins at the same time under neuronal promoters, however 
without any linking Ca2+ binding unit. This thy1-YFP16xCFP-23 transgenic line did not show 
any significant ratio changes in the setting of EAE (see Figure 12). Third, oxidative tissue 
damage has been described as a pronounced feature in EAE and MS (Fischer et al., 2012; 
Lassmann et al., 2012; Nikić et al., 2011). A direct effect of ROS/RNS on the sensor protein 
could be a potential confounder of Ca2+ measurements. In our experiments, the application of 
ROS/RNS on the spinal cord yielded a strong FRET increase (see Figure 16). At the same time, 
the parallel application of ROS/RNS and bepridil lead to diminished or almost no increase of 
axon FRET ratios (experiment series by C. Mahler, not shown). It is highly unlikely that a 
direct redox-mediated effect on the sensor protein could be diminished by a specific channel 
blocker (in this case bepridil). Therefore, we assumed no direct effect of ROS/RNS on our Ca2+ 
sensing proteins. 
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5.1.2 Interpretation of the measured signals  
As we are confident to have measured actual intra-axonal calcium signals in our paradigm, 
a key interest appears to be the interpretation of the measurements. A first important question 
is, what actual amount of Ca2+ correlates with the FRET ratios measured in the experiments. 
The empirical measure of the indicator affinity gives a sensible approximation to this 
problem: As calcium indicators differ largely in their affinities for calcium, the dissociation 
constant (Kd) is an important variable that reflects the likelihood that a complex of indicator 
and calcium ion will separate. In fact, it has a molar unit that equals the concentration of Ca2+ 
where half of the sensor proteins are Ca2+ bound (Grienberger and Konnerth, 2012). The Kd 
for CerTN-L15, the sensor protein mainly used in this study, is 1.2 µM (Heim et al., 2007). 
The other sensor that I tested, TN-XXL, has a described value of 800 nM (Mank et al., 2008). 
Both calcium indicators showed strong (up to 3-fold) FRET changes in the experimental 
paradigms of this study. Based on the dose response characteristics of the sensor this would 
correspond to calcium concentrations of >10-6 M.  
A precise calibration of the sensor readout with different calcium concentration e.g. in cell 
culture would not directly correlate with the actual in vivo data, since the Kd value can be 
changed by many parameters. These include pH, presence of Mg2+ and temperature – most of 
which are potentially changed in the setting of EAE (Grienberger and Konnerth, 2012). 
Therefore, we decided on a binary system to distinguish axons with largely elevated Ca2+ from 
others with baseline Ca2+ concentrations. Our criterium for “Ca2+ high” axons was a FRET 
ratio greater than a threshold of 3 SD over the mean control values. All values below this 
threshold we considered “Ca2+ low”. This approach likely gives a robust readout of actual and 
large-scale calcium increases compared to the control state in healthy animals. However, it 
might overlook many intermediate stages that could potentially present, as there was as well a 
variety amongst the group of “Ca2+ high” axons in our experiments.  To get a better idea of the 
exact ΔCa2+ measured, one would have to correlate different sensor readouts, including also 
synthetic calcium dyes like Oregon-Green-BAPTA-1 (OGB-1) and relate it to measured 
response curves in literature (Hendel et al., 2008). 
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One major confounder is the intrinsic buffer capacity that all sensors exhibit. There is a 
constant equilibrium of calcium ions that are either free or bound to calcium buffers. GECIs 
expressed in the measured cell add their buffering capacity to the total capacity of the 
endogenous buffers that include parvalbumin, calbindin-D28k and calretinin (Baimbridge et 
al., 1992). The intracellular calcium dynamics are therefore strongly dependent on the amount 
of indicator in the cell. However, this is more a feature relevant when looking at rise and decay 
times, giving low-affinity indicators (such as CerTN-L15 in this study) some better signal 
kinetics because of their smaller buffer capacity (Neher and Augustine, 1992). In our study, we 
could not detect a higher probability for axons with a strong expression pattern (and therefore 
higher signal intensity) to show different FRET ratio readouts (see Figure 10A). 
In the work of Direnberger et al., a broad assessment of different organs in mice 
expressing the sensor protein TN-XXL was done to check for any effects of the Ca2+ indicator 
on the physiology of the host organism. The study includes microarray expression profiling, 
anatomical analysis, behavioural testing and recording of basic physiological parameters. 
According to the authors, the vast majority of parameters tested did not differ between TN-
XXL transgenic mice and their littermates that were not transgenic (Direnberger et al., 2012). 
5.1.3 Potential improvements in signal detection 
In this work I showed calcium dynamics in a large population of degenerating axons. 
These signals appeared largely stable over space and time and only in very rare occasions, I 
was able to detect gradients of increased calcium that spread over the observed length of an 
axon (not shown). Whether or not this phenomenon was an imaging artefact still has to be 
ruled out. The spatial resolution in xy and z allowed for single axon detection in the dense 
population. However, it was not precise enough to resolve subcelluar structures of the axon 
like nodes of Ranvier and check for spatially confined Ca2+ changes that might occur. These 
might also include interactions with subcellular structures like mitochondria or the ER. 
Diffusion of sensor protein within the axon might also complicate measurement of localized 
Ca2+ transients. 
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 I frequently measured changes of axonal Ca2+ over time, as presented in chapter 4.5. 
However, these occurred over the time course of 2-4 hours, sampled in 20-40 min intervals. 
With the imaging equipment used, a much higher sampling speed would in principle be 
possible. The trade-off is a much smaller sampling area and, as a chief concern, potential 
phototoxicity. We therefore focused on the robust and slow Ca2+ dynamics of large 
populations. 
Calcium signals in neurons can in principal undergo rapid changes. In models of 
degenerative diseases like Alzheimer, neuronal hyperexcitability has been detected by imaging 
calcium transients, and this altered activity has been attributed to morphological alterations in 
dendrites (Busche et al., 2008; Palop et al., 2007; Sišková et al., 2014). The hyperactivity 
patterns occurred in a fast-paced manner of up to 0.25 Hz. Since the calcium transients in 
principal correlate with the action potential firing of neurons (Kerr et al., 2005; Wallace et al., 
2008), the sampling speed and the rise and decay time of the sensor must be able to reflect the 
measured dynamics. The low imaging frequency and the low affinity of our sensor did likely 
not reveal fast-paced Ca2+ alterations that take place in healthy and inert appearing axons, or 
even fluctuations in axons we addressed as “Ca2+ high”. A very different approach would 
implement low power but high frequency sampling (Chen et al., 2012) and possibly two 
different calcium sensors that work in a low-affinity and high-affinity range, respectively. 
Since the spectral variety of sensors has improved in the last few years (Walker et al., 2013), 
measuring a different Ca2+signal in two spectral bands would in principle be possible. Our 
collaborators that provided the Ca2+ sensor transgenic mice have in the meantime 
bioengineered their GECIs and developed a variant with higher fluorescent change, improved 
signal kinetics and created a potpourri of different affinity sensors (Thestrup et al., 2014). 
Using several variants of the “Twitch” family of sensors could potentially give a deeper insight 
to the Ca2+ dynamics seen in the neuroinflammatory paradigm. 
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5.2 Calcium predicts the fate of degenerating axons in inflammatory 
lesions 
In a related in vivo study in a model of contusion spinal cord injury, we showed the role of 
Ca2+ dynamics for the fate of axons to degenerate. At the first observation time point, few 
minutes after injury, over half of the axons showed elevated intra-axonal calcium levels. 
Interestingly, over time, elevated Ca2+ levels recovered to normal in some axons, while they 
persisted in others. Axons with persisting Ca2+ elevations were more prone to degenerate 
(Williams et al., 2014). We undertook a similar approach in the setting of neuroinflammation, 
as shown in this work. 
5.2.1 Calcium in focal axonal degeneration 
In this work I assessed axonal Ca2+ levels in the setting of acute lesions in the lumbar 
spinal cord of mice suffering EAE. One to three days after clinical disease onset, I could detect 
altered Ca2+ concentrations in a subset of the observed axon population. I was also able to 
reproduce the presence of focal axonal degeneration (FAD) stages as described by Nikic et al. 
The distribution of the observed axon population in the FAD stages (0: morphologically 
intact, 1: swollen and 2: fragmented axons) appeared comparable to the original study (Nikić 
et al., 2011). In a putative lesion, I attributed each axon a FAD stage and measured its Ca2+ 
level. A majority of almost 80 % of fragmented axons and approximately half of the swollen 
axons presented with high Ca2+. Among the normal appearing axons I could show that 
roughly 20% exhibit increased Ca2+ levels.  
The concept of focal axonal degeneration implies that it is a process that occurs at one or 
more discrete sites along the axon, synchronously and results in spreading fragmentation. 
Therefore, two major points are of interest when looking at axonal Ca2+ in EAE. Firstly, where 
in relation to inflammatory infiltration can one detect elevated Ca2+. Secondly, how is the Ca2+ 
distributed within the axon. To address this, we stained for cell nuclei in vivo to get an 
imaging correlate of the infiltrating immune cells and therefore label a putative lesion site. 
Well in line with prior studies, dense patches of infiltrating cells appear in the lumbar spinal 
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cord of EAE mice (Nikić et al., 2011; et al., 2013). Advanced stages of FAD and axons with 
elevated Ca2+ appear in these lesions. The stretch of an axon that could be analysed varied 
considerably, due to a dense labelling pattern that limits identification of an axon among its 
neighbours. In some instances I was able to track an axon over a length of ± 1 mm. Nearly all 
detected Ca2+ elevations expanded over the entire stretch of axon observed (not shown). Thus, 
Ca2+ elevations in EAE most likely correlate with inflammatory foci and affect a long stretch of 
an axon. However, it remains open whether an axon will still exhibit elevated Ca2+ in a more 
remote segment of the spinal cord cranial or caudal to the lesion site, and whether a gradient 
appears in relation to lesion sites. To address this question, a transgenic strain with a very 
sparse GECI labelling pattern would have to be studied, similar to the thy1-GFP-S mouse line 
(Feng et al., 2000). 
5.2.2 Assessing the predictive value of increased calcium 
In our experiments, the distribution of FAD stages appeared shifted towards fragmented 
axons (stage 2) in EAE remission (10-12 days after clinical onset) compared to the acute 
phase. At the same time, there were only few morphologically intact axons (stage 0) that 
exhibited elevated Ca2+. This implies that the population of stage 0/high Ca2+ axons are a 
feature of an acute lesion and either recover their Ca2+ towards the remission phase or 
degenerate and eventually fragment. 
The dynamic analysis of large axon populations (see chapter 4.5) allowed us to get an 
unprecedented view into the patterns and timecourse of Ca2+ and morphological changes in 
EAE lesions. As reflected in the diagram (Figure 15), we saw a large variety of transitions of 
the observed axons. Therefore we calculated the probability of an axon to undergo a certain 
change (per hour of observation) in order to get a clue about which of the changes happen 
more frequently than others. I drew three main conclusions on the basis of this diagram: First, 
both axonal swelling and fragmentation are more likely to happen with elevated intra-axonal 
Ca2+. Second, recovery of swellings appears more frequently in low-Ca2+ axons. Third, intact 
looking axons can change between states of increased and normal Ca2+. Taken together, this 
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implicates a predictive value of elevated Ca2+ levels in axons, indicating a high risk of 
subsequent degeneration when present. Nikic et al. assessed the transition probabilities in a 
comparable approach. The rates appeared to be in a similar range, with some variability. This 
is likely to be due to the different axon population imaged in the used transgenic lines and the 
pooling of the acute phase (onset+1 to onset+3) in this study.  
5.3 Sources and mechanisms of calcium overload 
Several mechanisms have been proposed to be involved in inflammatory axon 
degeneration, among these mitochondrial dysfunction and energy failure, as well as 
exposition to reactive oxygen and nitrogen species (ROS/RNS). These players could 
potentially all be linked to imbalances in intra-axonal Ca2+ levels. Mitochondrial dysfunction 
and the resulting energy depletion, together with the inflammatory demyelination, are 
presumed to lead to activation, dysfunction and altered distribution of ion channels (Friese et 
al., 2014). ROS/RNS could have both indirect effects on ion homeostasis by either acting on 
mitochondrial energy production or else by directly interfering with ion channel function or 
membrane integrity. Below, I will discuss these potential mediators of inflammatory axon 
degeneration and how they might be mechanistically linked to calcium dysregulation. 
5.3.1 Correlation with other mediators of inflammatory axon degeneration 
5.3.1.1 Mitochondrial damage 
Mitochondrial dysfunction and damage has been proposed to be a major cause of 
inflammatory axon degeneration (Dutta et al., 2006; Trapp and Stys, 2009). Damage to 
mitochondria can be detected both in chronically demyelinated axons of inactive lesions 
and in active inflammatory lesions, where infiltrating macrophages and activated 
microglia are present. It is possible that there may be distinct mechanisms of 
mitochondrial damage that can induce axon degeneration depending on the stage of the 
disease (Witte et al., 2014). The obvious, presumed effects of mitochondrial damage 
include energy failure and ion channel dysfunction, e.g. leading to overload of the 
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cytoplasm with Ca2+. A release of mitochondrial Ca2+ into the cytosolic compartment 
could also be possible.  
 In the setting of acute inflammatory lesions in EAE, our group has shown that 
mitochondrial alterations are an early ultrastructural sign of focal axonal degeneration. 
When quantifying the mitochondrial shape through a ratio of mitochondrial length and 
width, about 30 % of normal appearing axons (stage 0) already show signs of 
mitochondrial swelling and shortening. Interestingly, the demyelination of these axons 
was not a necessary prerequisite for these mitochondrial alterations. In addition, when the 
mitochondrial membrane potential was measured, it showed that concomitant functional 
changes occurred with altered shape. In brain biopsies from multiple sclerosis patients, 
altered mitochondrial shapes could be also seen, appearing both in morphologically intact 
and in swollen axons (Nikić et al., 2011). Moreover, our lab has detected widespread 
transport deficits in EAE, which even precede structural alterations of axons, cargos, or 
microtubules (Sorbara et al., 2014). Taken together, this data proposes that there could 
both be problems with function and distribution of mitochondria. 
Chronic lesions contain a large population of axons that have survived the acute 
inflammatory attack but stay demyelinated. However, a certain percentage of these axons 
will eventually degenerate. Mahad and colleagues showed deficiency of complex IV of the 
respiratory chain in injured axons in MS. These changes were accompanied by 
accumulations of APP and non-phosphorylated neurofilament-SMI-32, which are 
markers of transport failure and degeneration of axons (Mahad et al., 2009). Interestingly, 
in some axons in chronic MS lesions that did not show accumulations of these markers 
there was also evidence of compensatory upregulation of complex II and complex IV 
activities. Another study showed an increase of mitochondrial size and respiratory chain 
enzyme activity in demyelinated but uninjured axons (Witte et al., 2009). 
This impairment of mitochondrial function could contribute to axonal degeneration as 
proposed by the “virtual-hypoxia” hypothesis: One important function of axonal 
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mitochondria is the synthesis of ATP by oxidative phosphorylation. Chronic challenge 
with ROS/RNS can lead to an impairment of energy production by accumulating 
mutations in the mitochondrial DNA (Lin and Beal, 2006). However, axons have a large 
energy demand and need the majority of their available ATP to maintain ionic 
equilibrium during information processing (Howarth et al., 2012). At the same time, 
evidence speaks for an even increased energy demand in demyelinated lesions: Lack of 
myelin in otherwise intact axons changes ion channel distribution, in particular sodium 
channels (Craner et al., 2004a), leading to increased energy consumption to keep up 
conductivity of the affected axon. Taken together, the imbalance of chronic failure in ATP 
production, increased exposition to ROS/RNS and higher energy demand would induce a 
state of “virtual hypoxia” in demyelinated CNS lesions. The occurrence of tissue acidosis 
and the induction of hypoxia-inducible factor-1a (HIF-1α) shown in neuroinflammatory 
lesions are consistent with such a process (Friese et al., 2014; Trapp and Stys, 2009). This is 
highly relevant for this study, since these mechanisms could lead to an overload of the 
axon with Na+ and Ca2+ through various pathways that will be discussed in chapter 5.3.2. 
5.3.1.2 Reactive oxygen and nitrogen species 
The changes in mitochondrial transport, shape and function in intact, myelinated axons 
make it likely that soluble factors are inducing these alterations. Reactive oxygen and 
nitrogen species have been widely suggested to be involved in MS pathogenesis. In vitro 
data suggests ROS/RNS as strong candidates for inflammatory axon degeneration 
(Higgins et al., 2010; Witte et al., 2010). In the work of Nikic et al., in vivo exposure of the 
spinal cord of healthy animals to ROS/RNS induced degenerative changes that were 
strikingly similar to those seen in focal axonal degeneration. I was able to reproduce this in 
our Ca2+ imaging paradigm. Interestingly, I could detect an increase in axonal Ca2+ in a 
majority of axons shortly after application of H2O2 to the spinal cord. The Ca2+ high axons 
were more prone to degenerate in a fashion similar to FAD (see Figure 16). A similar 
effect could be evoked by the addition of the NO donor spermine NONOate to a healthy 
spinal cord (experiments performed by Christoph Mahler, data not shown). 
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Both mitochondrial changes and intra-axonal Ca2+ elevation induced by ROS/RNS- 
application were thus similar to the axonal changes observed by our group in EAE. 
Furthermore, in vivo measurements in EAE have shown increased levels of H2O2 in spinal 
cords. When using ROS/RNS scavengers for treatment in the acute phase of the disease, 
the likelihood of axons undergoing FAD could be influenced by shifting them towards 
recovery (Nikić et al., 2011). This is well in line with the findings in MS, where strong 
evidence points to increased ROS/RNS production in inflamed areas (Haider et al., 2011; 
Smith and Lassmann, 2002).  
To better understand the effects of reactive species, it is worthwhile to take a closer look 
on the different molecules that are subsumed in these groups, their reactive potential and 
their possible sources. Therefore I will now discuss first the family of ROS, and afterwards 
RNS. 
Various forms of ROS exist: The most frequent types are superoxide (O2−) and its 
derivatives hydroxyl radical (OH∙) as well as hydrogen peroxide (H2O2). They vary in 
stability and their interactions with iron or copper in cells (Haider et al., 2011; van 
Horssen et al., 2011). Mononuclear phagocytes in MS lesions are able to produce ROS 
through enzymes including myeloperoxidase, xanthine and NADPH oxidases (NOX) 
(Fischer et al., 2012). ROS is capable of inducing damage to biological structures such as 
polyunsaturated fatty acids (PUFA) found in membrane lipids, functional proteins, and 
DNA/RNA. As the CNS exhibits high oxygen turnover and is rich in PUFA, it is 
particularly vulnerable to lipid peroxidation. In addition, oxidative damage to cellular 
membrane lipids generates 4-hydroxy-2-nonenal (4-HNE). This reactive aldehyde also 
appears toxic to CNS cells (van Horssen et al., 2011). 
The effects of RNS, specifically NO, can be manifold (Smith and Lassmann, 2002). In vitro 
studies suggest that high levels of NO can lead to the induction of conduction block and 
therefore axonal injury. Conduction appears to be especially blocked in demyelinated and 
early remyelinated axons that are exposed to NO (Redford et al., 1997; Smith et al., 2001). 
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Additionally, NO affects the components of the mitochondrial respiratory chain 
(Gonsette, 2008). When NO reacts with superoxide, it produces an especially potent toxic 
metabolite: peroxynitrate. Its strong oxidising and nitration activity affects proteins, lipids, 
DNA and carbohydrates. Peroxynitrite reacts also with tyrosine residues, resulting in 
nitrotyrosine (NT). The presence of the latter in MS lesions could be shown by 
immunohistochemistry (Gonsette, 2008; Liu et al., 2001; Oleszak et al., 1998).  Substantial 
levels of one major known producer of NO, iNOS, could be detected in MS lesions and co-
localized with macrophage/microglia markers (Hill et al., 2004). 
5.3.2 Mediators of calcium influx 
Intracellularly, Ca2+ is a tightly regulated ion. The concentration gradient across the 
plasma membrane spans from 10−3 M Ca2+ outside to 10−7 M Ca2+ inside the cell. 
Endoplasmic or axoplasmic reticulum and mitochondria are known to be important 
intracellular reservoirs of Ca2+ that can release or buffer the ion and even cycle it between 
them, for example during apoptosis. There are a multitude of channels and transporters 
that carefully regulate both the in- and efflux of Ca2+ through the plasma membrane and 
the organelles, as shown in Figure 18. Pathological activation and/or deactivation of these 
mechanisms leads to aberrant Ca2+ levels within the axon, however, factors released by 
infiltrating immune cells might also be able to directly compromise axonal membrane 
integrity and lead to direct influx of Ca2+ from the extracellular space.  
In this study, I could show that Ca2+ levels are increased in a subset of degenerating axons 
in the spinal cord of animals during EAE. In addition, I could show that such increased 
Ca2+ levels can rapidly be induced by the application of either ROS or RNS, leading to 
subsequent degeneration. This suggests that the model of ROS/RNS mediated axonal 
degeneration is a valuable paradigm to assess the effect of these mediators on Ca2+ influx. 
There are at least three possible mechanisms how ROS/RNS could induce such a Ca2+ 
influx: (i) a direct attack on the axonal membrane, (ii) the direct activation/deactivation of 
Ca2+ conducting channels and transporters (iii) an indirect effect through the activation of 
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the  “virtual hypoxia” pathway that ultimately results in Ca2+ overload. I will discuss the 
three mechanisms and how they could be addressed experimentally in the following 
paragraphs.  
5.3.2.1 Membrane disruption 
In chapter 5.3.1.2 the different species that are subsumed under the term ROS/RNS were 
introduced. Metabolites like peroxynitrate are aggressive enough to affect all kinds of 
biological matter, including membrane lipids. Also, the specific tendency of ROS to attack 
poly-unsaturated fatty acids (PUFA) points towards a potential effect on the axolemma 
through lipid peroxidation. This mechanism has drawn attention in MS, however mainly 
concerning oligodendrocyte pathology (Juurlink et al., 1998). The formation of membrane 
disruptions stable enough to allow for large-scale Ca2+ influx in axons has been shown in 
vivo by our group in a model of spinal cord contusion (I contributed to this study as a 
collaborator). In these experiments, a strong Ca2+ increase after contusion could be 
suppressed by chelating extracellular Ca2+ with EGTA. To check for pore formation, 
fluorescently conjugated macromolecules (0.8 kD cadaverine or 10 kD dextran) were 
loaded into the subdural space before contusion. These molecules remained excluded 
from axons in the healthy spinal cord but got taken up after contusion by a large number 
of axons. Around 75% of the Ca2+ elevated axons appeared to have taken up the dye when 
loaded 15 minutes after contusion, suggesting the existence of axonal pores that permit the 
entry of Ca2+ and even the comparatively much larger dye molecules, and that persist at 
least for some time after the initial injury. The fate of the axons was positively influenced 
when the pores spontaneously resealed during the observed period (Williams et al., 2014). 
Although spinal cord contusion is a different model with a mechanical impact preceding 
pore formation, the existence of membrane pores could also be a plausible explanation for 
Ca2+ entry into axons passing through EAE lesions. One putative mechanism for the 
formation of pores in the axolemma is lipid peroxidation, nitration or related effects by 
ROS/RNS. 
Discussion 
 
66 
5.3.2.2 Direct effects on Ca2+ channels 
 
Figure 18  Ca2+ conducting structures of the axonal and organelle membranes 
A variety of channels and transporters have been described to be existent in an axon and its organelles. A 
majority of them could potentially react to ROS/RNS exposition or energy failure. 
ROS/RNS could also act directly on Ca2+ conducting channels and transporters. Ca2+ flux 
through both the outer membrane and the release from intracellular stores is tightly 
regulated in cells. It has become increasingly clear that many Ca2+ channels are modulated 
by ROS/RNS, which in fact perform a broad range of physiological, regulatory functions in 
cells. Among the channels that have been described to be influenced by redox changes are 
the ryanodine receptor, IP3 receptor, Ca2+ ATPases in the sarcoplasmic reticulum 
(SERCA) or plasma membrane (PMCA and NCX), voltage gated calcium channels 
(VGCC), members of the TRP family, glutamate receptors as well as the permeability 
transition pore (PTP) in mitochondria (Waring, 2005). In a series of experiments done by 
my colleague Christoph Mahler, we aimed to pharmacologically block a selection of the 
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channels mentioned above in vivo, in the experimental paradigms of ROS or RNS-
mediated axon damage in the spinal cord. We observed the strongest effect both on 
calcium rise and subsequent degeneration when blocking the reverse action of the 
sodium-calcium exchanger (NCX) of the plasma membrane with Bepridil and KB-R7943. 
The effect was more pronounced in the setting of NO mediated degeneration, suggesting a 
direct effect of NO on the NCX (C. Mahler, personal communication). However, the 
described effects could also be attributed to the virtual hypoxia hypothesis, as explained in 
the next paragraph. 
5.3.2.3 Energy failure and virtual hypoxia pathway 
The third possible mechanism of redox-mediated Ca2+ influx is an indirect path: The 
reduction or halt of oxidative phosphorylation in mitochondria due to elevated levels of 
endogenous and/or exogeneous ROS/RNS can lead to the lack of ATP. The resulting 
failure of energy-dependent pumps like the Na+/K+ ATPase leads to accumulation of intra-
axonal Na+. To extrude Na+ from the cytosol, the NCX would start operating in reverse 
mode and ultimately increase the concentration of cytosolic Ca2+. Interfering with these 
mechanisms as the final pathway of “virtual hypoxia”, in particular sodium blockade with 
phenytoin or flecainide, have partly been shown to alleviate symptoms in EAE and EAN 
(Bechtold et al., 2004; 2005; Black et al., 2006; Morsali et al., 2013). Another possibility 
would be the specific blockage of the reversely operating NCX, as described in the last 
paragraph. The strong protective effect we saw in our experiments when inhibiting the 
reversely operating NCX in redox mediated axon damage with bepridil could therefore be 
due to this indirect pathway and not, as discussed above, through a direct activation by 
ROS/RNS. The idea of linked Ca2+ and Na+ overload in NO mediated degeneration is 
supported by in vivo electrophysiological experiments showing conduction block after 
application of NO on spinal root axons. In an in vitro preparation, these researchers were 
also able to diminish degeneration of these axons by the application of lidocaine, 
flecainide or bepridil (Kapoor et al., 2003). As bepridil is also an inhibitor of L-type 
voltage gated calcium channels, the protective effect is even stronger, since VGCC are 
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capable of amplifying Ca2+ influx by opening in response to depolarization. However, in 
the more complex case of EAE the effect of targeting this pathway is less clear. 
Interestingly, there is evidence that α1B, the pore-forming subunit of the N-type calcium 
channel, is accumulated within axons and axonal spheroids within demyelinating lesions 
in MS (Kornek et al., 2001) . As N-type VGCC are presumed to have their site of action at 
nerve terminals rather than at the internodal axolemma, this would point towards an 
effect of pathologically altered expression patterns of VGCCs in neuroinflammatory 
lesions that could contribute to increased intra-axonal Ca2+. 
To test the therapeutic effect of bepridil in EAE in a preliminary experiment, we 
implanted osmotic mini pumps containing a solution of bepridil or vehicle dissolved in 
aCSF in thy1-YFP16xMitoP mice showing weight loss just before the onset of clinical 
symptoms. Both groups received a continuous intrathecal delivery of solution over the 
timecourse of 2 days. In a blinded, fixed tissue analysis I looked at inflammatory foci 
(revealed by staining for infiltrating cell nuclei) for axonal pathology. Even though the 
clinical scores might show a barely significant treatment effect on day 3, I was not able to 
detect a significant difference in the distribution of FAD stages between the Bepridil and 
vehicle group. Therefore, we were not able to link the strong effects observed in ROS/RNS 
mediated axon damage with a reduced level of inflammatory axon damage. However, 
further assessment is needed at this point to determine, for example, whether in this 
delivery paradigm sufficiently high concentrations of drug reach the inflammatory lesions 
within the spinal cord. In this regard, measuring axonal Ca2+ dynamics in EAE mice 
implanted with either saline or bepridil pumps could provide useful information. 
5.3.2.4 Glutamate excitotoxicity 
However, it is not only ROS/RNS that likely challenges axons in EAE and MS. Exceeding 
levels of glutamate are seen as a potent mediator of neuronal death, through a mechanism 
referred to as excitotoxicity. The term stands for excess stimulation of neurons by 
neurotransmitters like glutamate or related molecules, leading to massive activation of 
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glutamate receptors such as AMPA and NMDA that it turn can lead to substantial influx 
of Ca2+ ions. This pathway is somewhat coupled with the situation in virtual hypoxia and 
redox-mediated damage: impaired mitochondria will neither be able to produce the 
energy needed to stop the overload of the cell with Ca2+, nor buffer it sufficiently, but 
rather release more Ca2+. Glutamate excitotoxicity and oxidative stress are thought to have 
a final common pathway and appear as the “evil twins” in many neurodegenerative 
diseases. In MS, studies implicate higher levels of glutamate or aspartate in the 
cerebrospinal fluid of patients, not just in acute relapses but also during clinically stable 
phases (Sarchielli et al., 2003; Stover et al., 1997). MR spectroscopy showed evidence of 
higher glutamate levels even in normal appearing white matter of MS patients (Srinivasan 
et al., 2005). The amount of glutamate has been correlated with oligodendrocyte and axon 
damage in MS (Werner et al., 2001). In EAE, application of the AMPA/kainate antagonist 
NBQX yielded increased oligodendrocyte survival and reduced dephosphorylation of 
neurofilament H, indicating less axon damage. According to the authors, effects on lesion 
size and the degree of central nervous system inflammation were not observed (Pitt et al., 
2000).   
However these results remain open to interpretation, as it is unlikely that the systemic 
blockade of a widely distributed receptor like AMPA/kainate can specifically repress 
neuro-axonal overstimulation to prevent damage without effects on other CNS cells that 
might be involved in the phenomenon. In another interesting study using an adoptive 
transfer EAE model and in vivo imaging, Siffrin and colleagues observed direct interaction 
of MOG-specific Th17 cells and neuronal cells in demyelinating lesions that was associated 
with extensive axonal damage and intra-axonal calcium fluctuations (Siffrin et al., 2010). 
Their assessment showed the formation of immune synapses (‘kinapses’) at the point of 
interaction. By blocking NMDA receptors with MK-801, they were able to partially reverse 
the Ca2+ transients in vivo, supporting their hypothesis that it is T-cell derived glutamate 
which leads to overstimulation of neurons (Siffrin et al., 2010). The presence of receptors 
for excitatory molecules is assumed to be upregulated on neurons and/or 
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oligodendrocytes in MS, rendering these cells more vulnerable to excitotoxicity 
(Newcombe et al., 2008). One group has suggested expression of ionotropic glutamate 
receptors even in the membrane of axons in the spinal cord that could become harmful 
under pathological conditions (Ouardouz et al., 2009a; 2009b), which would make 
glutamate excitotoxicity a strong candidate for inducing the focal axonal degeneration 
observed in our paradigm. 
 
5.3.2.5 Other mechanisms 
Two other putative mechanisms of Ca2+ overload in degenerating axons of 
neuroinflammatory lesions appear somewhat linked but downstream to the combined 
effects of excitotoxicity and redox mediated energy depletion: the role of the 
mitochondrial permeability transition pore (MPTP) and acid-sensing ion channel-1 
(ASIC1). Forte et al. observed an improved recovery of EAE in mice lacking cyclophilin D 
(CyPD), a key regulator of the MPTP (Forte et al., 2007). Evidence presented a strong 
preservation of axons in the spinal cords of CypD knockout mice and an increased 
resistance to ROS/RNS of cultured CypD-/- neurons, probably due to an enhanced Ca2+ 
buffering capacity of mitochondria. By immunohistochemical staining they demonstrated 
that the effect was not due to reduced infiltration of inflammatory immune cells. This 
would imply that challenged mitochondria are taking part in axonal Ca2+ overload via the 
opening of the MPTP. 
A strong treatment effect has also been observed when knocking out, or pharmacologically 
blocking, ASIC1. This is a neuronally expressed, proton-gated channel that is permeable 
to Na+ and Ca2+. Friese and colleagues assessed pH levels in the spinal cord and were able 
to show tissue acidosis in the inflamed spinal cord (pH 6.60 ± 0.23) compared to controls 
(pH 7.41 ± 0.06). As this low pH is compatible with the activation of ASIC1, they 
proposed that the markedly reduced clinical deficit and reduced axonal degeneration of 
Asic1–/– mice compared to wild-type mice suffering EAE is due to less ion influx through 
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this channel. A tantalising aspect of this study is the use of amiloride, a blocker of ASIC 
and broadly used cardiovascular pharmaceutical, to mimic the effects seen in Asic1–/– mice. 
Again, as ASIC1 is known to be expressed on immune cells, the hypothesis that the 
protective effect is due to direct blockade of ASIC1 on neurons cannot be conclusively 
proven. However, adoptive transfer showed that ASIC mediated mechanisms of T-cells 
were not an important factor for the clinical effect seen in this study (Friese et al., 2007). 
   
5.3.3 Effects of Ca2+ overload 
Another important question that arises from our study is whether the Ca2+ elevations in 
EAE are capable of triggering degenerative processes in axons, and if so, how they lead to 
the eventual disintegration of axonal structures. As Ca2+ overload is often seen as one 
common step in a multitude of degeneration pathways, the factors that would appear 
“downstream” are highly interesting and maybe relevant for our understanding of 
neurodegeneration in MS and beyond. Importantly, additional targets for therapy could 
be identified in these downstream mechanisms. 
One possible downstream mechanisms of Ca2+ influx is the activation of Calpains, a 
protease family, which have been suggested to be key players in cytoskeletal degradation, 
for example, during Wallerian degeneration (George et al., 1995; Yang et al., 2013; Zhai et 
al., 2003). In vivo, application of calpain inhibitors was able to completely block acute 
axonal degeneration after the mechanic transection of spinal axons (Kerschensteiner et al., 
2005). In our work in the spinal cord contusion paradigm, calpain inhibitors likewise 
could protect axons for long periods of time (in vivo observation of up to 8 h) and were 
able to positively influence the fate of axons with increased Ca2+ levels (Williams et al., 
2014). These proteases could therefore be a key component that links Ca2+ influx to axonal 
dismantling in EAE and MS. In EAE, one study showed calpain to be upregulated in the 
optic nerve at the onset of the disease. These changes were attenuated following treatment 
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with calpeptin, a calpain inhibitor. However, inflammation, microgliosis and astrogliosis 
were also altered with the calpeptin treatment, and the aim of the study was not to study 
specifically axon degeneration (Das et al., 2013). Another group used the calpain inhibitor 
CYLA to treat EAE in mice. In their study, they were able to see a reduction of clinical 
signs, tissue calpain content, demyelination and inflammatory infiltration (Hassen et al., 
2008).  
Another element of the axonal injury cascade in neuroinflammation has been suggested 
recently in a study (Schattling et al., 2012), in which the transient receptor potential 
melastatin 4 (TRPM4) cation channel was proposed to be crucial in the process of axon 
degeneration and the accumulation of irreversible neurological disability. Either knockout 
of the TRPM4 protein or pharmacological inhibition using glibenclamide, an antidiabetic 
drug, resulted in reduced axonal and neuronal degeneration and ameliorated clinical 
disease scores in EAE. The channel’s expression was shown to be increased on axons in 
the inflamed spinal cord in mice and in the CNS of MS patients. The authors put great 
effort into excluding immune-related effects of TRPM4 deficiency: In one central 
experiment they established bone marrow–chimeric mice by reconstituting lethally 
irradiated Trpm4−/− or WT mice with either Trpm4−/− or WT bone marrow, showing that 
immune cells deficient for Trpm4 were not responsible for the reduced disease severity 
that they reported (Schattling et al., 2012). As the TRPM4 channel is known to be 
activated by intracellular Ca2+ rises (Launay et al., 2002) and deactivated by ATP, it 
becomes highly relevant in respect to our study as a potential amplifier of Ca2+ induced 
degeneration. Also, the authors point out the osmotic effect of large-scale Na+ influx 
through this channel, which could be one explanation to the swellings seen in axons 
undergoing FAD. 
5.4 Future therapeutic strategies 
During the last few decades, MS research and clinical management have made great  
progress regarding the acute inflammatory components of MS. Reducing both the clinical 
Discussion 
 
73 
severity and the frequency of relapses has become possible – a big relief for patients 
suffering from RR-MS. However, the underlying mechanisms of neurodegeneration as the 
cause of irreversible disability are still far from being understood. Finding a drug to 
reduce, halt or ideally even prevent progressive worsening of neurological deficits in long-
time MS patients would be an immense success that would benefit all patients. 
A strategy to develop such new therapeutic approaches has to first focus on the system 
where the pharmacological interventions are being tested in: In this case, one has to 
consider whether EAE is a suitable animal model that resembles MS closely enough 
concerning the aspects of the disease that one wants to characterize. EAE models have 
been proven vital for studying general concepts as well as specific processes of 
autoimmunity and a lot of our knowledge about MS is derived from this rodent model. 
However, as with many other rodent models of a human disease, many of the preclinical, 
experimental studies showing strong therapeutic success in EAE actually have failed to 
show the same efficacy in MS. When critically reviewing the weaknesses of EAE, the 
following aspects are in focus: First, most of the models’ variants are no spontaneous 
disease. They therefore do not reproduce the likely quite heterogeneous mechanisms that 
induce MS but rather produce a prominent TH1-cell or TH17 response promoted by the 
combination of mycobacteria and complete freuds adjuvant. Second, the timecourse in 
classical acute EAE appears to be rather that of a post-infectious demyelinating disease 
than of actual relapsing-remitting and secondary progressive MS. Third, general 
differences between human versus laboratory animal populations provide further 
complications: inbred, pathogen-free mice with a fixed diet are compared with all sorts of 
human ethnicities, dietary habits and environmental factors from different parts of the 
world (Friese et al., 2006). However, many of the listed differences between MS and EAE 
focus on the aetiology and immunopathogenesis of the diseases. In this and related 
studies, we assess the fundamental principles of axonal damage in a neuroinflammatory 
setting. The aetiology of the disease becomes secondary in this kind of paradigm. It has 
been shown that in terms of the principle constitution of CNS inflammatory lesions, the 
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mouse model and the human disease share many common aspects. As our approach is a 
mechanistic one, which looks at the effects of immune cells and their released molecules 
on axonal structures, I believe that EAE and its spinal cord lesions is a suitable model. A 
drug that could specifically target one of these mechanisms would be an ideal candidate 
for a translational approach and a new treatment strategy that aims at neuroprotection 
rather than immunomodulation. 
On the basis of the evidence presented in this and other studies, ion dysregulation 
(specifically Ca2+) appears to be one of the important drivers of neuronal and axonal 
demise during EAE and MS. Some ion channels show adaptive changes to the 
inflammatory milieu by altering their relative distribution on the neuronal and axonal 
membrane, potentially even relocalizing from the soma to the axon. Amongst these are the 
NaV, VGCC, TRPM4 and ASIC1a ion channels. Although these channels have been shown 
to take part in axonal degeneration, one could hypothesize that their axonal re-
distribution could have some initial benefits in keeping the axon intact and preserving its 
proper functioning. If one aims to intervene in this system, it remains crucial to 
understand these different expression patterns and solve what relative contribution the 
different channels make in allowing pathological ion flux and therefore degeneration of 
the axons (Friese et al., 2014). In the following paragraphs, I will briefly discuss some 
translational approaches that have been undertaken so far: 
Significant, likely neuroprotective effects of voltage-gated sodium channel blockade have 
been shown in EAE (Bechtold et al., 2004; Kapoor et al., 2003). This clinical efficacy could 
however not be translated to patients as shown recently in a randomised, double-blind, 
placebo-controlled, parallel-group trial of lamotrigine (a widely used anticonvulsive drug) 
in patients with secondary progressive MS. The effect of lamotrigine on cerebral volume of 
patients with SP-MS did not differ from that of placebo over 24 months. It even seemed to 
cause early volume loss that reversed partially on discontinuation of treatment (Kapoor et 
al., 2010).   
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Backed by strong effects both on the clinical score of mice, and on the reduction of axonal 
and myelin damage seen in histopathological analysis, preclinical efficacy of amiloride has 
been well documented in the EAE model. The fact that it did not exhibit strong 
modulation of tissue inflammation, and targets the ASIC channel that is overexpressed on 
CNS axons, makes chances high that its effects are mainly neuroprotective (see chapter 
5.3.2). As the drug has been in use for many years for the treatment of hypertension and 
congestive cardiac failure, a group of researchers led by L. Fugger and J. Palace initiated a 
translational study and started treating a cohort of 14 PP-MS patients with amiloride. It 
will be highly interesting to see the outcome of this pilot study and a potential 
randomized, controlled trial assessing the effects of this novel treatment strategy (Arun et 
al., 2013). 
The critical role of the NMDA receptor in glutamate-mediated excitotoxicity has driven 
the quest to find suitable antagonists as neuroprotective agents. This therapeutic strategy 
has been especially pursued in conditions of ischemia like stroke or brain injury. Even 
though a lot of resources have been spent to find treatment strategies that tackle NMDA-
mediated neuronal damage, large clinical studies have failed so far. Furthermore NMDA 
antagonists have several adverse CNS effects, including hallucinations, a centrally 
mediated increase in blood pressure and, at high doses, catatonia and anesthesia (Kemp 
and McKernan, 2002). Therefore it remains hard to predict whether a specific and 
effective targeting of glutamate-mediated axon damage will at some point prove to be an 
applicable treatment for MS. 
In work previous to my study, my colleagues could effectively halt degeneration of axons 
and mitochondrial changes in the inflamed spinal cord with scavengers of ROS/RNS. This 
strategy yielded robust results and potentially interferes with the interaction of immune 
cells and the neuro-axonal compartment (Nikić et al., 2011; Sorbara et al., 2014). Two 
recent studies reported protective properties in different EAE models of a synthetic 
antioxidant called “MitoQ”. It specifically accumulates in mitochondria, and did not seem 
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to alter levels of inflammation. Ideally, this agent would protect mitochondria against ROS 
and therefore reduce axonal damage (Mao et al., 2013). There is also evidence that 
activation of the Nrf2/ARE pathway might play a protective role in the pathogenesis of 
MS, however not just by neuroprotection. Hence, further activation of the Nrf2/ARE 
system via monofunctional inducers could prove an effective strategy. Notably, dimethyl-
fumarate (DMF) and its primary metabolite monomethyl fumarate (MMF) are potent 
activators of this pathway (van Horssen et al., 2011). As DMF (BG-12, Tecfidera®) has 
been just introduced as a new, oral drug to treat RR-MS, this mechanism will be of special 
interest, especially when assessing the long-term effects of the treatment. In principle, 
antioxidant treatment to tackle neuro-axonal degeneration in MS seems to be a promising 
candidate. However, many issues, mainly concerning pharmacokinetics but also target 
specificity, still have to be solved.  
 
5.5 Concluding remarks 
Multiple sclerosis, with its enigmatic etiology and complex pathophysiology has been 
baffling researches for many years now. In recent years the focus of investigation has 
broadened, and neurobiological aspects such as the immune-mediated damage of neurons 
and their axons are being explored. These aspects are of substantial clinical importance as the 
gradually increasing disability appears to be a clinical correlate of progressive loss of axonal 
connections. The interactions of immune cells with axons are potentially responsible for this 
demise. However the exact mechanisms of the degeneration process remain elusive. As the 
detailed analysis of pathological mechanisms in animal models provides a solid basis for 
translational approaches, investigating the molecular mediators of axonal degeneration in MS 
models remains a promising approach to find future neuroprotective therapies for MS and 
related diseases. 
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In this work I established an imaging approach to monitor changes in intra-axonal 
calcium concentrations with single axon resolution in the spinal cord of living animals. In 
actively induced EAE, the most common mouse model of MS, I showed that Ca2+ is a critical 
factor mediating axon degeneration in inflammatory lesions. With elevated Ca2+ 
concentrations, the probability increases that an axon will first swell and afterwards fragment,  
although there also appears to be chances for an axon to recover - both in terms of returning 
to normal Ca2+ levels and in the fact that swellings can subsequently disappear. This renders 
the process very interesting, as it suggests that it might be accessible for intervention. 
Therefore one has to discover, how the rise in Ca2+ is induced and which molecular players 
mediate it.  
I have discussed a broad range of potential mechanisms of Ca2+ entry into the intra-axonal 
compartment. I have emphasized the effects of ROS/RNS, which can have a large spectrum of 
possible indirect and direct effects on structures that can mediate Ca2+ elevation in an axon. 
As preceding work in our group has drawn a link between immune-released ROS/RNS and 
focal axonal degeneration, the mechanistic details including the Ca2+ rise remain highly 
interesting and have to be further assessed. The related mechanisms of the “virtual hypoxia” 
pathway also need to be re-evaluated in the context of this work. Additionally, the relevance of 
glutamate excitotoxicity for the described processes remains a key interest in the field and is 
also directly linked to intra-axonal Ca2+. Even though it is technically challenging to assess the 
individual contribution of these pathways to axonal demise in a complex neuroinflammatory 
environment, it stays a highly promising field for pharmacological intervention. 
While the first clinical studies of potentially neuroprotective agents in MS have been 
performed in the last decade, the results of these (largely failed) studies suggest that there is 
still a long way to go. However, in the large variety of compounds that are approved and in 
daily use in modern medicine, there might be many hidden pearls to be tested for their 
neuroprotective potential in EAE and MS – which would bypass at least one phase of clinical 
testing and therefore save some years in development. As I cited the MS patient M. Lemelle in 
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the beginning of this thesis, patients are in constant anxiety to accept and adapt to the new 
challenges brought by disease progression. Research must move forward in understanding the 
complex processes of MS and how they are linked. It must translate this into treatment 
strategies that allow patients to maintain a “normal” daily life and thus fundamentally 
improve its quality. 
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